1
|
Mauro M, Bignardi D, Baiardini I, Bonadonna P, Braschi MC, Emiliani F, Guerra L, Liberati S, Olivieri F, Pravettoni V, Preziosi D, Ridolo E, Rivolta F, Martini M, Bilò MB. Health-related Quality of Life in Hymenoptera Venom Allergy: Validation of the Italian version of the Vespid Allergy Quality of Life Questionnaire (VQLQ-i). Eur Ann Allergy Clin Immunol 2024. [PMID: 38235503 DOI: 10.23822/eurannaci.1764-1489.325] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2024]
Affiliation(s)
- M Mauro
- Allergy Unit, Division of Pulmonology, S. Anna Hospital, ASST-Lariana, Como, Italy
| | - D Bignardi
- Allergology Unit, IRCCS San Martino Polyclinic Hospital, Genoa, Italy
| | | | - P Bonadonna
- Allergy Unit and Asthma Center, Verona University Hospital, Verona, Italy
| | - M C Braschi
- Allergy Unit, Department of Internal Medicine, University Hospital Ospedali Riuniti, Ancona, Italy
| | - F Emiliani
- Allergy Unit, AUSL della Romagna, Faenza, Italy
| | - L Guerra
- Allergology Unit, IRCCS San Martino Polyclinic Hospital, Genoa, Italy
| | - S Liberati
- Allergy Unit, Ospedale Infermi di Rimini, Rimini, Italy
| | - F Olivieri
- Allergy Unit and Asthma Center, Verona University Hospital, Verona, Italy
| | - V Pravettoni
- Department of Internal Medicine, IRCCS Foudation Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - D Preziosi
- Allergy Unit, Division of Pulmonology, S. Anna Hospital, ASST-Lariana, Como, Italy
| | - E Ridolo
- Allergy and Immunology, University of Parma, Parma, Italy
| | - F Rivolta
- Department of Internal Medicine, IRCCS Foudation Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - M Martini
- Allergy Unit, Department of Internal Medicine, University Hospital Ospedali Riuniti, Ancona, Italy
- Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy
| | - M B Bilò
- Allergy Unit, Department of Internal Medicine, University Hospital Ospedali Riuniti, Ancona, Italy
- Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy
| |
Collapse
|
2
|
Arzt-Gradwohl L, Annik Herzog S, Aberer W, Alfaya Arias T, Antolín-Amérigo D, Bonadonna P, Boni E, Bożek A, Chełmińska M, Ernst B, Frelih N, Gawlik R, Gelincik A, Hawranek T, Hoetzenecker W, Jiménez Blanco A, Kita K, Kendirlinan R, Košnik M, Laipold K, Lang R, Marchi F, Mauro M, Nittner-Marszalska M, Poziomkowska-Gęsicka I, Pravettoni V, Preziosi D, Quercia O, Reider N, Rosiek-Biegus M, Ruiz-Leon B, Schrautzer C, Serrano P, Sin A, Ayşe Sin B, Stoevesandt J, Trautmann A, Vachová M, Johannes Sturm G. Influencing factors on the safety and effectiveness of venom immunotherapy. J Investig Allergol Clin Immunol 2023; 35:0. [PMID: 37937715 DOI: 10.18176/jiaci.0967] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2023] Open
Abstract
BACKGROUND AND OBJECTIVE The safety profile of venom immunotherapy (VIT) is a relevant issue and considerable differences in safety and efficacy of VIT have been reported. The primary aim of this study was to evaluate the safety of ACE inhibitors and beta-blockers during VIT, which has already been published. For a second analysis, data concerning premedication and venom preparations in relation to systemic adverse events (AE) during the up-dosing phase and the first year of the maintenance phase were evaluated as well as the outcome of field stings and sting challenges. METHODS The study was conducted as an open, prospective, observational, multicenter study. In total, 1,425 patients were enrolled and VIT was performed in 1,342 patients. RESULTS Premedication with oral antihistamines was taken by 52.1% of patients during the up-dosing and 19.7% of patients during the maintenance phase. Taking antihistamines had no effect on the frequency of systemic AE (p=0.11) but large local reactions (LLR) were less frequently seen (OR: 0.74; 95% CI: 0.58-0.96; p=0.02). Aqueous preparations were preferentially used for up-dosing (73.0%) and depot preparations for the maintenance phase (64.5%). The type of venom preparation neither had an influence on the frequency of systemic AE nor on the effectiveness of VIT (p=0.26 and p=0.80, respectively), while LLR were less frequently seen when depot preparations were used (p<0.001). CONCLUSION Pretreatment with oral antihistamines during VIT significantly reduces the frequency of LLR but not systemic AE. All venom preparations used were equally effective and did not differ in the frequency of systemic AE.
Collapse
Affiliation(s)
- L Arzt-Gradwohl
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| | - S Annik Herzog
- Institute for Medical Informatics, Statistics, and Documentation, Medical University of Graz, Graz, Austria
| | - W Aberer
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| | - T Alfaya Arias
- Allergy Department, Hospital Universitario Fundación Alcorcón, Madrid, Spain
| | - D Antolín-Amérigo
- Servicio de Enfermedades del Sistema Inmune-Alergia, Hospital Universitario Príncipe de Asturias, Departamento de Medicina y Especialidades Médicas, Universidad de Alcalá, Madrid, Spain
- Servicio de Alergia, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain
| | - P Bonadonna
- Allergy Unit, Verona General Hospital, Verona, Italy
| | - E Boni
- Laboratorio Unico Metropolitano, Maggiore Hospital, Bologna, Italy
| | - A Bożek
- Clinical Department of Internal Diseases, Dermatology, and Allergology, Medical University of Silesia, Zabrze, Poland
| | - M Chełmińska
- Allergology Department, Medical University of Gdańsk, Gdańsk, Poland
| | - B Ernst
- Department of Dermatology, General Hospital Ordensklinikum Linz GmbH Elisabethinen, Linz, Austria
| | - N Frelih
- University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia
| | - R Gawlik
- Department of Internal Medicine, Allergy, and Clinical Immunology, Silesian University of Medicine, Katowice, Poland
| | - A Gelincik
- Department of Internal Medicine, Division of Immunology and Allergic Diseases, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye
| | - T Hawranek
- Department of Dermatology and Allergology, Paracelsus Medical University Salzburg, Salzburg, Austria
| | - W Hoetzenecker
- Department of Dermatology, Kepler University Hospital and Medical Faculty, Johannes Kepler University, Linz, Austria
| | - A Jiménez Blanco
- Allergy Unit, Hospital Central de la Cruz Roja. Faculty of Medicine, Alfonso X El Sabio University, ARADyAL, Madrid, Spain
| | - K Kita
- Allergology Department, Medical University of Gdańsk, Gdańsk, Poland
| | - R Kendirlinan
- Department of Pulmonary Diseases, Division of Immunology and Allergy, Faculty of Medicine, Ankara University, Ankara, Türkiye
| | - M Košnik
- University Clinic of Respiratory and Allergic Diseases, Golnik and Medical Faculty Ljubljana, Slovenia
| | - K Laipold
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| | - R Lang
- Department of Dermatology and Allergology, Paracelsus Medical University Salzburg, Salzburg, Austria
| | - F Marchi
- SD Allergologia Clinica, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
| | - M Mauro
- Allergy Unit, Sant´Anna Hospital, Como, Italy
| | - M Nittner-Marszalska
- Department of Internal Diseases, Pulmonology and Allergology, Medical University of Wroclaw, Wroclaw, Poland
| | | | - V Pravettoni
- Department of Internal Medicine, Fondazione IRCCS Ca´ Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - D Preziosi
- Allergy Unit, Sant´Anna Hospital, Como, Italy
| | - O Quercia
- High Specialization Unit of Allergology, Hospital of Faenza, AUSL (Local Health Unit) of Romagna, Romagna, Italy
| | - N Reider
- Department of Dermatology, Venereology, and Allergology, Medical University of Innsbruck, Innsbruck, Austria
| | - M Rosiek-Biegus
- Department of Internal Diseases, Pulmonology and Allergology, Medical University of Wroclaw, Wroclaw, Poland
| | - B Ruiz-Leon
- Allergy Section of University Hospital Reina Sofia, ARADyAL Network, Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, Spain
| | - C Schrautzer
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| | - P Serrano
- Allergy Section of University Hospital Reina Sofia, ARADyAL Network, Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, Spain
| | - A Sin
- Department of Internal Medicine, Division of Allergy and Immunology, Medical Faculty, Ege University, Izmir, Türkiye
| | - B Ayşe Sin
- Department of Pulmonary Diseases, Division of Immunology and Allergy, Faculty of Medicine, Ankara University, Ankara, Türkiye
| | - J Stoevesandt
- Department of Dermatology and Allergy, University Hospital Würzburg, Würzburg, Germany
| | - A Trautmann
- Department of Dermatology and Allergy, University Hospital Würzburg, Würzburg, Germany
| | - M Vachová
- Department of Immunology and Allergology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
- Department of Immunology and Allergology, University Hospital Pilsen, Czech Republic
| | - G Johannes Sturm
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
- Allergy Outpatient Clinic Reumannplatz, Vienna, Austria
| |
Collapse
|
3
|
Barocco G, Palei M, Croci E, Savoia A, Mauro M, Stuto F. Guidelines for outsourcing collective catering services in the Friuli Venezia Giulia region. Eur J Public Health 2022. [DOI: 10.1093/eurpub/ckac131.227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Issue
Many stakeholders involved in collective catering services (CCS) of schools, hospitals, elderly care homes, and workplaces of the autonomous region of Friuli Venezia Giulia (ARFVG) have reported some non-compliance with the nutritional, environmental or social standards required by public administrations (PA) procurement contracts (PC), which included the recommendations of the WHO, EU, Ministry of Health, and Ministry of the Environment (MHE).
Description of the problem
The ARFVG prevention plans have set the goal to overcome the critical issues of the regional CCS which serve over 10% of the population (130,000 meals a day). Between 2019 and 2021, a multidisciplinary group of experts from health services and from the association of 215 regional municipalities developed the guidelines (GL) for outsourcing of CCS. The aim was to support PA in the drafting of PC, evaluation of offers and verification of contractual performance. Reference was made to Dir. 2014/24/EU, EU green public procurement criteria for food, catering services and vending machines, the national lines for CCS of MHE. The GL are characterized by the integration between the tender document models and the 8 qualification areas detailed in: restructuring; supplies; environmental impact and sustainability; production processes; personnel qualification and training; nutritional standards; customer satisfaction; and verification and research of quality.
Results
Two regional central purchasing bodies have already used the GL to draft the PC for school CCS of 26 municipalities and for the whole hospital CCS of RAFVG. The application of guidelines in PC has introduced homogeneous high level qualification and verification standards for the CCS of the RAFVG.
Lessons
To ensure the application of food, nutritional, environmental and social policies in CCS, it is essential to activate networks between professionals from different sectors in order to share tools to achieve the common sustainable development goals.
Key messages
• To integrate food, nutritional, environmental and social regional policies into collective catering services, it is essential to apply systemic tools shared by all Public Administrations.
• Central purchasing bodies have the potential to introduce homogeneous and shared high level qualification and verification standards for collective catering services.
Collapse
Affiliation(s)
- G Barocco
- Servizio Igiene Alimenti e Nutrizione, Azienda Sanitaria Universitaria Giuliano Ison , Trieste, Italy
| | - M Palei
- Servizio Prevenzione, Sicurezza Alimentare, Direzione Centrale Salute, Regione FVG , Trieste, Italy
| | - E Croci
- Servizio Igiene Alimenti e Nutrizione, Azienda Sanitaria Universitaria Giuliano Ison , Trieste, Italy
| | - A Savoia
- Servizio Igiene Alimenti e Nutrizione, Azienda Sanitaria Universitaria Friuli Centra , Udine, Italy
| | - M Mauro
- Servizio Igiene Alimenti e Nutrizione, Azienda Sanitaria Universitaria Friuli Centra , Udine, Italy
| | - F Stuto
- Servizio Igiene Alimenti e Nutrizione, Azienda Sanitaria Friuli Occidentale , Pordenone, Italy
| |
Collapse
|
4
|
Pravettoni V, Mauro M, Rivolta F, Consonni D, Cappelletti C, Chiei Gallo A, Sangalli A, Bilò MB. Venom immunotherapy: safety and tolerability of the build-up phase with depot versus aqueous preparations. Clin Exp Allergy 2022; 52:1230-1233. [PMID: 35904013 PMCID: PMC9796821 DOI: 10.1111/cea.14209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2022] [Revised: 07/14/2022] [Accepted: 07/21/2022] [Indexed: 01/26/2023]
Affiliation(s)
- Valerio Pravettoni
- UOC General Medicine Immunology and AllergologyFoundation IRCCS Ca’ Granda Ospedale Maggiore PoliclinicoMilanItaly
| | - Marina Mauro
- U.O.S. AllergologyHospital S. Anna Como ASST LarianaComoItaly
| | - Federica Rivolta
- UOC General Medicine Immunology and AllergologyFoundation IRCCS Ca’ Granda Ospedale Maggiore PoliclinicoMilanItaly
| | - Dario Consonni
- Epidemiology UnitFoundation IRCCS Ca’ Granda Ospedale Maggiore PoliclinicoMilanItaly
| | | | | | - Andrea Sangalli
- Allergy and Clinical Immunology ResidencyUniversity of MilanItaly
| | - Maria Beatrice Bilò
- DISCLIMO (Department of Clinical and Molecular Sciences)Università Politecnica delle MarcheAnconaItaly
- Allergy Unit, Department of Internal MedicineUniversity Hospital Ospedali RiunitiAnconaItaly
| |
Collapse
|
5
|
Mauro M, Cammilleri G, Celi M, Cicero A, Arizza V, Ferrantelli V, Vazzana M. Effects of diclofenac on the gametes and embryonic development of Arbacia lixula. The European Zoological Journal 2022. [DOI: 10.1080/24750263.2022.2059582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Affiliation(s)
- M. Mauro
- Tecnologie Biologiche, Chimiche e Farmaceutiche (STEBICEF), Università di Palermo, Dipartimento di Scienze e, Palermo, Italia
| | - G. Cammilleri
- Istituto Zooprofilattico Sperimentale della Sicilia A. Mirri, Palermo, Italia
| | - M. Celi
- Tecnologie Biologiche, Chimiche e Farmaceutiche (STEBICEF), Università di Palermo, Dipartimento di Scienze e, Palermo, Italia
| | - A. Cicero
- Istituto Zooprofilattico Sperimentale della Sicilia A. Mirri, Palermo, Italia
| | - V. Arizza
- Tecnologie Biologiche, Chimiche e Farmaceutiche (STEBICEF), Università di Palermo, Dipartimento di Scienze e, Palermo, Italia
| | - V. Ferrantelli
- Istituto Zooprofilattico Sperimentale della Sicilia A. Mirri, Palermo, Italia
| | - M. Vazzana
- Tecnologie Biologiche, Chimiche e Farmaceutiche (STEBICEF), Università di Palermo, Dipartimento di Scienze e, Palermo, Italia
| |
Collapse
|
6
|
Incorvaia C, Ridolo E, Mauro M, Pucciarini F, Heffler E, Canonica GW. Venom Immunotherapy and Aeroallergen Immunotherapy: How Do Their Outcomes Differ? Front Allergy 2022; 3:854080. [PMID: 35386638 PMCID: PMC8974810 DOI: 10.3389/falgy.2022.854080] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2022] [Accepted: 01/24/2022] [Indexed: 11/13/2022] Open
Abstract
Allergen immunotherapy (AIT) and venom immunotherapy (VIT) are meant to work on the causes of allergies, respectively, to respiratory allergens and Hymenoptera venom, inducing tolerance to the allergens and modifying the natural history of allergy. Both types of immunotherapies have evidence of efficacy, but actually they present wide differences in both effectiveness and safety. Indeed, as far as the effectiveness of VIT is concerned, if the protection against fatal reactions to stings is considered as the primary objective, more than 40 years of clinical practice demonstrate complete success. The clinical success of AIT is measurable on the basis of reduction or disappearance of allergic symptoms. The difference between the two treatments is even higher as regards safety: AIT has been concerned in the past by a series of fatal reactions caused, which underwent a progressive decrease when it was understood that they were related to the presence of uncontrolled asthma. However, fatal reactions related to failure to recognize the presence of risk factors or administration errors are still reported. Similarly to what has been observed for efficacy, VIT has never been affected by fatal reactions to the administration of venom, and the most important risk of anaphylaxis, which is the concomitance of mastocytosis, is now identified by measuring its marker serum tryptase. To date, mechanisms of hypersensitivity reactions that differentiate respiratory allergy from Hymenoptera venom allergy have not been successfully demonstrated. We have examined the past and present literature in order to propose reasonable hypotheses about the mechanisms actually involved.
Collapse
Affiliation(s)
- Cristoforo Incorvaia
- Allergy and Clinical Immunology, Medicine and Surgery Department, University of Parma, Parma, Italy
| | - Erminia Ridolo
- Allergy and Clinical Immunology, Medicine and Surgery Department, University of Parma, Parma, Italy
| | | | - Francesco Pucciarini
- Allergy and Clinical Immunology, Medicine and Surgery Department, University of Parma, Parma, Italy
| | - Enrico Heffler
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
- Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital, Rozzano, Italy
- *Correspondence: Enrico Heffler
| | - Giorgio Walter Canonica
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
- Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital, Rozzano, Italy
| |
Collapse
|
7
|
Sturm GJ, Herzog SA, Aberer W, Alfaya Arias T, Antolín‐Amérigo D, Bonadonna P, Boni E, Bożek A, Chełmińska M, Ernst B, Frelih N, Gawlik R, Gelincik A, Hawranek T, Hoetzenecker W, Jiménez Blanco A, Kita K, Kendirlinan R, Košnik M, Laipold K, Lang R, Marchi F, Mauro M, Nittner‐Marszalska M, Poziomkowska‐Gęsicka I, Pravettoni V, Preziosi D, Quercia O, Reider N, Rosiek‐Biegus M, Ruiz‐Leon B, Schrautzer C, Serrano P, Sin A, Sin BA, Stoevesandt J, Trautmann A, Vachová M, Arzt‐Gradwohl L. β-blockers and ACE inhibitors are not a risk factor for severe systemic sting reactions and adverse events during venom immunotherapy. Allergy 2021; 76:2166-2176. [PMID: 33605465 PMCID: PMC8359427 DOI: 10.1111/all.14785] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2020] [Revised: 01/06/2021] [Accepted: 01/20/2021] [Indexed: 11/28/2022]
Abstract
Background There is controversy whether taking β‐blockers or ACE inhibitors (ACEI) is a risk factor for more severe systemic insect sting reactions (SSR) and whether it increases the number or severity of adverse events (AE) during venom immunotherapy (VIT). Methods In this open, prospective, observational, multicenter trial, we recruited patients with a history of a SSR and indication for VIT. The primary objective of this study was to evaluate whether patients taking β‐blockers or ACEI show more systemic AE during VIT compared to patients without such treatment. Results In total, 1,425 patients were enrolled and VIT was performed in 1,342 patients. Of all patients included, 388 (27.2%) took antihypertensive (AHT) drugs (10.4% took β‐blockers, 11.9% ACEI, 5.0% β‐blockers and ACEI). Only 5.6% of patients under AHT treatment experienced systemic AE during VIT as compared with 7.4% of patients without these drugs (OR: 0.74, 95% CI: 0.43–1.22, p = 0.25). The severity of the initial sting reaction was not affected by the intake of β‐blockers or ACEI (OR: 1.14, 95% CI: 0.89–1.46, p = 0.29). In total, 210 (17.7%) patients were re‐stung during VIT and 191 (91.0%) tolerated the sting without systemic symptoms. Of the 19 patients with VIT treatment failure, 4 took β‐blockers, none an ACEI. Conclusions This trial provides robust evidence that taking β‐blockers or ACEI does neither increase the frequency of systemic AE during VIT nor aggravate SSR. Moreover, results suggest that these drugs do not impair effectiveness of VIT. (Funded by Medical University of Graz, Austria; Clinicaltrials.gov number, NCT04269629).
Collapse
Affiliation(s)
- Gunter Johannes Sturm
- Department of Dermatology and Venereology Medical University of Graz Graz Austria
- Allergy Outpatient Clinic Reumannplatz Vienna Austria
| | - Sereina Annik Herzog
- Center for Health Economics Research and Modelling Infectious Diseases (CHERMID) Vaccine & Infectious Disease Institute (VAXINFECTIO) University of Antwerp Antwerp Belgium
- Institute for Medical Informatics, Statistics, and Documentation Medical University of Graz Graz Austria
| | - Werner Aberer
- Department of Dermatology and Venereology Medical University of Graz Graz Austria
| | - Teresa Alfaya Arias
- Allergy UnitHospital General Universitario de Ciudad Real & Hospital Universitario Fundación Alcorcón Madrid Spain
| | - Darío Antolín‐Amérigo
- Servicio de Enfermedades del Sistema Inmune‐Alergia Hospital Universitario Príncipe de Asturias Departamento de Medicina y EspecialidadesMédicas Universidad de Alcalá Madrid Spain
- Servicio de Alergia Hospital Universitario Ramón y Cajal (IRYCIS Madrid Spain
| | | | - Elisa Boni
- Laboratorio Unico Metropolitano Maggiore Hospital Bologna Italy
| | - Andrzej Bożek
- Clinical Department of Internal Diseases, Dermatology, and Allergology Medical University of Silesia Zabrze Poland
| | - Marta Chełmińska
- Allergology Department Medical University of Gdańsk Gdańsk Poland
| | - Barbara Ernst
- Department of Dermatology General Hospital Ordensklinikum Linz GmbH Elisabethinen Linz Austria
| | - Nina Frelih
- University Clinic of Respiratory and Allergic Diseases Golnik Slovenia
| | - Radoslaw Gawlik
- Department of Internal Medicine, Allergy, and Clinical Immunology Silesian University of Medicine Katowice Poland
| | - Asli Gelincik
- Department of Internal Medicine Division of Immunology and Allergic Diseases Istanbul Faculty of Medicine Istanbul University Istanbul Turkey
| | - Thomas Hawranek
- Department of Dermatology and Allergology Paracelsus Medical University Salzburg Salzburg Austria
| | - Wolfram Hoetzenecker
- Department of Dermatology Kepler University Hospital and Medical FacultyJohannes Kepler University Linz Austria
| | - Aránzazu Jiménez Blanco
- Allergy Unit Hospital Central de la Cruz Roja Faculty of Medicine Alfonso X El Sabio UniversityARADyAL Madrid Spain
| | - Karolina Kita
- Allergology Department Medical University of Gdańsk Gdańsk Poland
| | - Reşat Kendirlinan
- Department of Pulmonary Diseases Division of Immunology and Allergy Faculty of Medicine Ankara University Ankara Turkey
| | - Mitja Košnik
- University Clinic of Respiratory and Allergic Diseases, Golnik and Medical Faculty Ljubljana Ljubljana Slovenia
| | - Karin Laipold
- Department of Dermatology and Venereology Medical University of Graz Graz Austria
| | - Roland Lang
- Department of Dermatology and Allergology Paracelsus Medical University Salzburg Salzburg Austria
| | - Francesco Marchi
- SD Allergologia ClinicaAzienda Ospedaliero‐Universitaria Pisana Pisa Italy
| | | | - Marita Nittner‐Marszalska
- Department of Internal Diseases, Pulmonology and Allergology Medical University of Wroclaw Wroclaw Poland
| | | | - Valerio Pravettoni
- UOC General Medicine Immunology and Allergology IRCCS Foundation CaGranda Ospedale Maggiore Policlinico Milan Italy
| | | | - Oliviero Quercia
- High Specialization Unit of Allergology Hospital of Faenza AUSL (Local Health Unit) of Romagna Romagna Italy
| | - Norbert Reider
- Department of Dermatology, Venereology, and Allergology Medical University of Innsbruck Innsbruck Austria
| | - Marta Rosiek‐Biegus
- Department of Internal Diseases, Pulmonology and Allergology Medical University of Wroclaw Wroclaw Poland
| | - Berta Ruiz‐Leon
- Maimonides Biomedical Research Institute of Cordoba (IMIBICAvenida Menéndez Pidal S/N Córdoba Spain
- Unidad de GestiónClínica de Inmunoalergia & ARADyAL Research Network Reina Sofía University Hospital Córdoba Spain
| | - Christoph Schrautzer
- Department of Dermatology and Venereology Medical University of Graz Graz Austria
| | - Pilar Serrano
- Maimonides Biomedical Research Institute of Cordoba (IMIBICAvenida Menéndez Pidal S/N Córdoba Spain
- Unidad de GestiónClínica de Inmunoalergia & ARADyAL Research Network Reina Sofía University Hospital Córdoba Spain
| | - Aytül Sin
- Department of Internal Medicine Division of Allergy and Immunology Medical Faculty Ege University Izmir Turkey
| | - Betül Ayşe Sin
- Department of Pulmonary Diseases Division of Immunology and Allergy Faculty of Medicine Ankara University Ankara Turkey
| | - Johanna Stoevesandt
- Department of Dermatology and Allergy University Hospital Würzburg Würzburg Germany
| | - Axel Trautmann
- Department of Dermatology and Allergy University Hospital Würzburg Würzburg Germany
| | - Martina Vachová
- Department of Immunology and Allergology Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic
| | - Lisa Arzt‐Gradwohl
- Department of Dermatology and Venereology Medical University of Graz Graz Austria
| |
Collapse
|
8
|
Bilò MB, Pravettoni V, Mauro M, Bonadonna P. Treating venom allergy during COVID-19 pandemic. Allergy 2021; 76:949-950. [PMID: 32677059 PMCID: PMC7404889 DOI: 10.1111/all.14473] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2020] [Revised: 05/30/2020] [Accepted: 06/17/2020] [Indexed: 11/30/2022]
Affiliation(s)
- Maria Beatrice Bilò
- Department of Clinical and Molecular Sciences Polytechnic University of Marche Ancona Italy
- Ancona and Allergy Unit Department of Internal Medicine University Hospital of Ancona Ancona Italy
| | - Valerio Pravettoni
- U.O.C. General Medicine – Immunology and Allergology Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy
| | - Marina Mauro
- U.O.S. Allergology ‐ Sant’Anna Hospital ASST Lariana Como Italy
| | - Patrizia Bonadonna
- U.S.D. Allergy Unit Integrated University‐Hospital of Verona Verona Italy
| |
Collapse
|
9
|
Bilò MB, Corsi A, Pravettoni V, Bignardi D, Bonadonna P, Quercia O, Mauro M, Novembre E, Micheletti R, Papa R. Development of a model care pathway for the management of Hymenoptera venom allergy: evidence-based key interventions and indicators. Clin Transl Allergy 2020; 10:8. [PMID: 32158533 PMCID: PMC7055031 DOI: 10.1186/s13601-020-00312-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2019] [Accepted: 02/24/2020] [Indexed: 01/18/2023] Open
Abstract
Background Hymenoptera venom allergy (HVA) is an underestimated condition representing an important cause of morbidity and mortality worldwide. Preventing future allergic reactions in patients who have already developed a systemic reaction is based on the correct management of the acute phase of the reaction followed by a correct diagnosis and, where indicated, prescription of adrenaline autoinjectors and VIT. A possible strategy to optimize care processes and to improve outcomes is the implementation of a Diagnostic and Therapeutic Care Pathways, also known as Integrated Care Pathways or Clinical Pathways (CPWs). The aim of the care pathway is to enhance the quality of care by improving risk‐adjusted patient outcomes, promoting patient safety, increasing patient satisfaction, and optimizing the use of resources. To our knowledge, currently in Italy as well as in Europe, there is no CPWs codified for the management of HVA patients. This paper describes the development of the clinical content of a care pathway for the management of HVA. Methods The methodology applied is based on the eight step method to build the clinical content of an evidence-based care pathway suggested by Lodewijckx et al. Results Three hundred and seventeen different clinical activities were extracted from the selected literature. The expert panel was involved in their evaluation, expressing a judgment of relevance through the Delphi study. As a result, 126 clinical activities were appraised to be valid and feasible. The final recommendations (126) were translated into 123 key interventions. Six indicators were produced by the clinical activities. Conclusion A set of 123 key interventions and of six process indicators were found to be appropriate for the development and standardization of the clinical content of the Hymenoptera venom allergy care pathway.
Collapse
|
10
|
Piapan L, De Michieli P, Ronchese F, Rui F, Mauro M, Peresson M, Segat L, D'Agaro P, Negro C, Bovenzi M, Larese Filon F. COVID-19 outbreak in healthcare workers in hospitals in Trieste, North-east Italy. J Hosp Infect 2020; 106:626-628. [PMID: 32805309 PMCID: PMC7427613 DOI: 10.1016/j.jhin.2020.08.012] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2020] [Accepted: 08/11/2020] [Indexed: 11/30/2022]
Affiliation(s)
- L Piapan
- Unit of Occupational Medicine, Department of Medical Sciences, University of Trieste, Trieste, Italy
| | - P De Michieli
- Unit of Occupational Medicine, Department of Medical Sciences, University of Trieste, Trieste, Italy
| | - F Ronchese
- Unit of Occupational Medicine, Department of Medical Sciences, University of Trieste, Trieste, Italy
| | - F Rui
- Unit of Occupational Medicine, Department of Medical Sciences, University of Trieste, Trieste, Italy
| | - M Mauro
- Unit of Occupational Medicine, Department of Medical Sciences, University of Trieste, Trieste, Italy
| | - M Peresson
- Unit of Occupational Medicine, Department of Medical Sciences, University of Trieste, Trieste, Italy
| | - L Segat
- Unit of Public Health, Department of Medical Sciences, University of Trieste, Trieste, Italy
| | - P D'Agaro
- Unit of Public Health, Department of Medical Sciences, University of Trieste, Trieste, Italy
| | - C Negro
- Unit of Occupational Medicine, Department of Medical Sciences, University of Trieste, Trieste, Italy
| | - M Bovenzi
- Unit of Occupational Medicine, Department of Medical Sciences, University of Trieste, Trieste, Italy
| | - F Larese Filon
- Unit of Occupational Medicine, Department of Medical Sciences, University of Trieste, Trieste, Italy.
| |
Collapse
|
11
|
Costantino MT, Romanini L, Gaeta F, Stacul F, Valluzzi RL, Passamonti M, Bonadonna P, Cerri G, Pucci S, Ricci P, Savi E, Galluzzo M, Mauro M, Grassedonio E, Yacoub MR, Reginelli A, Testi S, Ridolo E, Nettis E, Di Leo E, Rossi O, Montuschi P, Incorvaia C, Romano A. SIRM-SIAAIC consensus, an Italian document on management of patients at risk of hypersensitivity reactions to contrast media. Clin Mol Allergy 2020; 18:13. [PMID: 32765190 DOI: 10.1186/s12948-020-00128-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2019] [Accepted: 07/02/2020] [Indexed: 12/20/2022] Open
Abstract
Hypersensitivity reactions (HRs) to contrast media (CM) can be distinguished in immune-mediated (including allergic reactions) and non-immune-mediated reactions, even if clinical manifestations could be similar. Such manifestations range from mild skin eruptions to severe anaphylaxis, making it important for radiologists to know how to identify and manage them. A panel of experts from the Società Italiana di Radiologia Medica e Interventistica (SIRM) and the Società Italiana di Allergologia, Asma e Immunologia Clinica (SIAAIC) provided a consensus document on the management of patients who must undergo radiological investigations with CM. Consensus topics included: the risk stratification of patients, the identification of the culprit CM and of a safe alternative by an allergy workup, as well as the use of premedication and the correct procedure to safely perform an elective (i.e., scheduled) or urgent examination. The most important recommendations are: (1) in all patients, a thorough medical history must be taken by the prescribing physician and/or the radiologist to identify at-risk patients; (2) in patients with hypersensitivity reactions to CM, the radiologist must consider an alternative, non-contrast imaging study with a comparable diagnostic value, or prescribe a different investigation with another class of CM; (3) if such options are not feasible, the radiologist must address at-risk patients to a reference centre for an allergy evaluation; (4) if timely referral to an allergist is not viable, it is recommended to use a CM other than the responsible one, taking into account cross-reactivity patterns; in the case of patients with histories of severe reactions, the presence of an anesthesiologist is also recommended and a premedication is suggested.
Collapse
Affiliation(s)
| | - Laura Romanini
- Radiology, Istituti Ospitalieri di Cremona, ASST Cremona, Cremona, Italy
| | - Francesco Gaeta
- Allergy Unit, Columbus Hospital, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Via Moscati n.30, Rome, Italy
| | - Fulvio Stacul
- Department of Radiology, Ospedale Maggiore, Azienda Sanitaria Universitaria Integrata di Trieste, Trieste, Italy
| | - Rocco Luigi Valluzzi
- Allergy Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Vatican City, Italy
| | | | - Patrizia Bonadonna
- Allergy Unit, Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy
| | - Giovanni Cerri
- Department of Radiology, ASST Spedali Civili di Brescia, Brescia, Italy
| | - Stefano Pucci
- Allergy Unit. General Hospital, Civitanova Marche, Milan, Italy
| | - Paolo Ricci
- Department of Radiology, Oncologiche ad Anatomopatologiche, Azienda Policlinico Umberto I, Sapienza Università di Roma, Rome, Italy
| | - Eleonora Savi
- Departmental Unit of Allergology, Guglielmo da Saliceto Hospital, Piacenza, Italy
| | - Michele Galluzzo
- Department of Radiology, Azienda Ospedaliera San Camillo Forlanini, Ospedale San Camillo, Rome, Italy
| | | | - Emanuele Grassedonio
- Department of Radiology, Dipartimento di Biopatologia e Biotecnologie Mediche, Policlinico Paolo Giaccone, Università degli Studi di Palermo, Palermo, Italy
| | - Mona Rita Yacoub
- Allergy and Immunology Department, IRCCS San Raffaele Hospital, Milan, Italy
| | - Alfonso Reginelli
- Department of Radiology & Radiotherapy, University of Campania 'Luigi Vanvitelli', Naples, Italy
| | - Sergio Testi
- Allergy and Clinical Immunology Unit, San Giovanni di Dio's Hospital, Florence, Italy
| | - Erminia Ridolo
- Department of Medicine and Surgery Clinical, University of Parma, Via Gramsci 14, 43126 Parma, Italy
| | - Eustacchio Nettis
- Department of Emergency and Organ Transplantation, School of Allergology and Clinical Immunology, University of Bari Aldo Moro, Bari, Italy
| | - Elisabetta Di Leo
- Section of Allergy and Clinical Immunology, Unit of Internal Medicine, "F. Miulli" Hospital, Acquaviva delle Fonti, Bari, Italy
| | - Oliviero Rossi
- Allergy Unit, Azienda Ospedaliero Universitaria Careggi, Florence, Italy
| | - Paolo Montuschi
- Pharmacology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.,Department of Pharmacology, Faculty of Medicine, Catholic University of the Sacred Heart, Rome, Italy
| | | | - Antonino Romano
- IRCCS Oasi Maria S.S., Troina & Fondazione Mediterranea G.B. Morgagni, Catania, Italy
| |
Collapse
|
12
|
Asero R, Abbadessa S, Aruanno A, Barilaro G, Barzaghi C, Bignardi D, Bilò MB, Borro M, Bresciani M, Busa M, Buzzulini F, Cavaliere C, Cecchi L, Ciccarelli A, Cortellini G, Cucinelli F, Deleonardi G, Emiliani F, Farsi A, Ferrarini E, Franchini M, Ingrassia A, Lippolis D, Losappio L, Marra AM, Martini M, Masieri S, Mauro M, Mazzolini M, Muratore L, Murzilli F, Nucera E, Pastorello EA, Pinter E, Polillo BR, Pravettoni V, Quercia O, Rizzi A, Russello M, Sacerdoti C, Scala E, Scala G, Scarpa A, Schroeder J, Uasuf CG, Villalta D, Yang B, Mistrello G, Amato S, Lidholm J. Detection of Gibberellin-Regulated Protein (Peamaclein) Sensitization among Italian Cypress Pollen-Sensitized Patients. J Investig Allergol Clin Immunol 2020; 32:40-47. [DOI: 10.18176/jiaci.0542] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
13
|
Larese Filon F, Miani A, Corradin M, Belloni Fortina A, Mauro M. Quaternium‐15 sensitization in the north‐east of Italy, trend from 1996 to 2016 and occupational role. J Eur Acad Dermatol Venereol 2020; 34:e317-e319. [DOI: 10.1111/jdv.16222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- F. Larese Filon
- Unit of Occupational Medicine University of Trieste Trieste Italy
| | - A. Miani
- Unit of Occupational Medicine University of Trieste Trieste Italy
| | - M.T. Corradin
- Dermatologic Unit Ospedale di Santa Maria degli Angeli Pordenone Italy
| | | | - M. Mauro
- Unit of Occupational Medicine University of Trieste Trieste Italy
| |
Collapse
|
14
|
Asero R, Aruanno A, Bresciani M, Brusca I, Carollo M, Cecchi L, Cortellini G, Deleonardi G, Farsi A, Ferrarini E, Gabrielli G, Ingrassia A, Mauro M, Murzilli F, Nucera E, Onida R, Pastorello EA, Pinter E, Rizzi A, Russello M, Sacerdoti C, Scala E, Scala G, Villalta D, Zampogna S, Amato S, Mistrello G. Evaluation of two commercial peach extracts for skin prick testing in the diagnosis of hypersensitivity to lipid transfer protein. A multicenter study. Eur Ann Allergy Clin Immunol 2020; 53:168-170. [PMID: 32347686 DOI: 10.23822/eurannaci.1764-1489.144] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Summary The clinical usefulness of two commercial peach extracts for SPT (by Lofarma SpA and ALK-Abellò, respectively) was compared in a multicenter study carried out in Italy. Peach allergic patients were tested with the two extracts in parallel and underwent the detection of IgE specific for all three peach allergens currently available (Pru p1, Pru p3, and Pru p4, respectively). The two extracts were almost identical in terms of sensitivity and specificity, being able to detect virtually all patients sensitized to stable peach allergens (lipid transfer protein (LTP) and, presumably, peamaclein) but scoring negative in patients exclusively sensitive to labile allergens (either PR-10 and/or profilin). Thus, the two extracts represent an excellent tool to carry out a preliminary component-resolved diagnosis of peach allergy at the first patient visit.
Collapse
Affiliation(s)
- R Asero
- Allergology Clinic, Clinica San Carlo, Paderno Dugnano, Milan, Italy
| | - A Aruanno
- Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy
| | - M Bresciani
- Allergology Clinic, Asl RM 4, S. Paolo Civitavecchia Hospital, Civitavecchia, Italy
| | - I Brusca
- Clinical Pathology U.O.C., Buccheri La Ferla F.B.F. Hospital, Palermo, Italy
| | - M Carollo
- Pathology and Clinical Biochemistry, Magna Graecia University, Catanzaro, Italy
| | - L Cecchi
- Allergology and Immunology SOS, Prato-Azienda USL Toscana Centro, Prato, Italy
| | - G Cortellini
- Romagna Allergy Unit, Internist Department of Rimini, Rimini, Italy
| | - G Deleonardi
- Laboratorio Unico Metropolitano, AUSL Bologna, Bologna, Italy
| | - A Farsi
- Allergology and Immunology SOS, Prato-Azienda USL Toscana Centro, Prato, Italy
| | - E Ferrarini
- Allergology OUS, Umberto I Hospital, Siracusa, Italy
| | - G Gabrielli
- School of Specialization in Allergy and Clinical Immunology, Alma Mater Studiorum, Bologna, Italy
| | - A Ingrassia
- Allergology UO, District of Marsala, ASP 9, Trapani, Italy
| | - M Mauro
- Allergology UO, ASST Lariana, Como, Italy
| | - F Murzilli
- Allergology U.O.S.D., S.S. Filippo e Nicola Hospital, Avezzano, Italy
| | - E Nucera
- Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy
| | - R Onida
- Clinical Pathology U.O.C., Buccheri La Ferla F.B.F. Hospital, Palermo, Italy
| | - E A Pastorello
- Struttura Complessa di Allergologia e Immunologia, ASST GOM, Niguarda, Milan, Italy
| | - E Pinter
- Clinic Immunology U.O.C., Policlinico Umberto Primo, Rome, Italy
| | - A Rizzi
- Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy
| | - M Russello
- Allergology UO, ASST Lariana, Como, Italy
| | | | - E Scala
- Istituto Dermopatico dell'Immacolata, Rome, Italy
| | - G Scala
- Allergology UOSD, Loreto Crispi, ASL Napoli 1 Centro, Naples, Italy
| | - D Villalta
- Immunology and Allergology Unit, Santa Maria degli Angeli Hospital, Pordenone, Italy
| | - S Zampogna
- Pediatric First Aid, Pugliese Ciaccio Hospital, Catanzaro, Italy
| | - S Amato
- Lofarma SpA, R and D, Milan, Italy
| | | |
Collapse
|
15
|
Bilò MB, Martini M, Pravettoni V, Bignardi D, Bonadonna P, Cortellini G, Kosinska M, Macchia D, Mauro M, Meucci E, Nittner‐Marszalska M, Patella V, Pio R, Quercia O, Reccardini F, Ridolo E, Rudenko M, Severino M. Large local reactions to Hymenoptera stings: Outcome of re-stings in real life. Allergy 2019; 74:1969-1976. [PMID: 31074868 DOI: 10.1111/all.13863] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2019] [Revised: 04/08/2019] [Accepted: 04/11/2019] [Indexed: 01/14/2023]
Abstract
BACKGROUND Large local reaction to Hymenoptera stings is usually defined as a swelling >10 cm which lasts longer than 24 hours, sometimes associated with erythema, pruritus and blisters. Currently, the risk of subsequent systemic reactions after re-stings is considered low (2%-15%). Therefore, a diagnostic workup in case of large local reaction is often judged unnecessary, as well as adrenaline auto-injector and venom immunotherapy prescription. The aim of this study was to prospectively evaluate the outcome of re-stings in a real-world setting, in patients with a history of one previous large local reaction. METHODS We consecutively enrolled patients who experienced their first large local reaction (as per EAACI definition), treated with antihistamine and steroids. They were followed for field re-stings and assessed for risk of subsequent systemic reactions. RESULTS We enrolled 662 patients. Out of the 225 re-stung subjects, 24% did not experience reactions, 52% reported a second large local reaction and 24% had systemic reactions. The risk of subsequent systemic reactions was higher in case of skin test reactivity to Apis mellifera or Vespula species (OR 2.1 and 3.8, respectively), in particular if positive at 0.001 µg/mL concentration (OR 13.4 and 16.5, respectively). CONCLUSIONS Systemic reactions, after a previous large local reaction, occur more frequently than that reported by literature. After analysing the predictive role of large local reactions for systemic reactions, we demonstrated that an accurate diagnostic workup may be considered, particularly skin tests. Further studies in different countries are needed to confirm these results and large local reaction management.
Collapse
Affiliation(s)
- Maria Beatrice Bilò
- Allergy Unit, Department of Clinical and Molecular Sciences Università Politecnica delle Marche Ancona Italy
| | - Matteo Martini
- Allergy and Clinical Immunology School Università Politecnica delle Marche Ancona Italy
| | - Valerio Pravettoni
- General Medicine, Immunology and Allergy Unit ‐ IRCCS Foudation Ca’ Granda Ospedale Maggiore Policlinico Milan Italy
| | | | - Patrizia Bonadonna
- U.S.D. Allergology Integrated University‐Hospital of Verona Verona Italy
| | - Gabriele Cortellini
- Allergy Unit, Internal Medicine Department, Rimini Hospital Local Health Unit of Romagna Rimini Italy
| | - Magdalena Kosinska
- Department of Internal Diseases and Allergology Medical University of Wroclaw Wroclaw Poland
| | | | - Marina Mauro
- UOS Allergology ASST Lariana Sant'Anna Hospital Como Italy
| | - Elisa Meucci
- Allergy Unit, Hospital S. Giovanni di Dio Florence Italy
| | | | - Vincenzo Patella
- Division Allergy and Clinical Immunology, Department of Medicine ASL Salerno "Santa Maria della Speranza" Hospital Salerno Italy
| | - Roberta Pio
- A.O.U San Giovanni di Dio e Ruggi d'Aragona Salerno Italy
| | - Oliviero Quercia
- High Specialization Unit of Allergology, Hospital of Faenza AUSL (Local Health Unit) of Romagna Faenza Italy
| | - Federico Reccardini
- SOC Pneumologia‐Fisiopatologia Respiratoria, Azienda Sanitaria Universitaria Integrata di Udine Udine Italy
| | - Erminia Ridolo
- Allergologia e Immunologia Clinica, Dipartimento di Medicina e Chirurgia Università degli studi di Parma Parma Italy
| | | | | |
Collapse
|
16
|
Mauro M, Crosera M, Bovenzi M, Basso P, Adami G, Maina G, Baracchini E, Larese Filon F. Corrigendum to “In vitro transdermal absorption of Al2O3 nanoparticles” Toxicol In Vitro, 2019 Apr 17;59:275-280. Toxicol In Vitro 2019; 59:322. [DOI: 10.1016/j.tiv.2019.05.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
17
|
Mauro M, De Grandis RA, Campos ML, Bauermeister A, Peccinini RG, Pavan FR, Lopes NP, De Moraes NV. Acid diterpenes from Copaiba oleoresin (Copaifera langsdorffii): Chemical and plasma stability and intestinal permeability using Caco-2 cells. J Ethnopharmacol 2019; 235:183-189. [PMID: 30763698 DOI: 10.1016/j.jep.2019.02.017] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/30/2018] [Revised: 02/04/2019] [Accepted: 02/10/2019] [Indexed: 06/09/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Copaiba oleoresin has been used in folk medicine in the treatment of bronchitis, syphilis, skin diseases and ulcers due to its anti-inflammatory and antiseptic activities, but there is no information about major compounds oral absorption to support the traditional use. AIM OF STUDY Considering the potential of copalic (CA) and kaurenoic acid (KA) - major biological activity (in vitro) diterpenes found in the oleoresin, this study aimed to evaluate the intestinal permeability of CA and KA using Caco-2 cells model as predictive test for oral drug absorption. MATERIALS AND METHODS Chemical stability at pH 1.2 and 7.4 and plasma stability were evaluated to mimic physiological conditions of the gastrointestinal tract. The intestinal permeability of CA and KA was evaluated in Caco-2 cells in the presence and absence of the P-glycoprotein inhibitor verapamil. RESULTS CA and KA were rapidly degraded at pH 1.2 (0.2 M Clark-Lubs buffer). At pH 7.4 (0.1 M phosphate buffer), CA was stable for up to 24 h and KA for up to 6 h. In human plasma, CA and KA can be considered stable for 24 h and 12 h at 37 °C, respectively. Caco-2 cells were considered viable when incubated with CA or KA in the range of 3.9-250 μM for 24 h. CA and KA exhibited moderate apparent permeability (Papp) of 4.67 (±0.08) × 10-6 cm/s and 4.66 (±0.04) × 10-6 cm/s, respectively. Simultaneous incubation with verapamil showed that P-glycoprotein does not play a relevant role on CA and KA oral absorption, with Papp of 4.48 (±0.26) × 10-6 cm/s and 5.37 (±0.72) × 10-6 cm/s observed for CA and KA, respectively. CONCLUSION The oral absorption of both CA and KA is driven by mainly passive permeability, is not limited by p-glycoprotein, but enteric-coated dosage forms should be used to avoid chemical instability in the gastric pH.
Collapse
Affiliation(s)
- M Mauro
- São Paulo State University (UNESP), School of Pharmaceutical Sciences, Araraquara, SP ZIP 14801-902, Brazil.
| | - R A De Grandis
- São Paulo State University (UNESP), School of Pharmaceutical Sciences, Araraquara, SP ZIP 14801-902, Brazil.
| | - M L Campos
- Federal University of Mato Grosso, Sinop, MT, Brazil.
| | - A Bauermeister
- University of Sao Paulo (USP), NPPNS, School of Pharmaceutical Sciences of Ribeirao Preto, Ribeirao Preto, SP ZIP 14040-903, Brazil.
| | - R G Peccinini
- São Paulo State University (UNESP), School of Pharmaceutical Sciences, Araraquara, SP ZIP 14801-902, Brazil.
| | - F R Pavan
- São Paulo State University (UNESP), School of Pharmaceutical Sciences, Araraquara, SP ZIP 14801-902, Brazil.
| | - N P Lopes
- University of Sao Paulo (USP), NPPNS, School of Pharmaceutical Sciences of Ribeirao Preto, Ribeirao Preto, SP ZIP 14040-903, Brazil.
| | - N V De Moraes
- São Paulo State University (UNESP), School of Pharmaceutical Sciences, Araraquara, SP ZIP 14801-902, Brazil.
| |
Collapse
|
18
|
Dusefante A, Mauro M, Belloni Fortina A, Corradin M, Larese Filon F. Contact allergy to methylchloroisothiazolinone/methylisothiazolinone in north‐eastern Italy: a temporal trend from 1996 to 2016. J Eur Acad Dermatol Venereol 2019; 33:912-917. [DOI: 10.1111/jdv.15453] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2018] [Accepted: 12/19/2018] [Indexed: 11/28/2022]
Affiliation(s)
- A. Dusefante
- Clinical Unit of Occupational Medicine University of Trieste Trieste Italy
| | - M. Mauro
- Clinical Unit of Occupational Medicine University of Trieste Trieste Italy
| | | | | | - F. Larese Filon
- Clinical Unit of Occupational Medicine University of Trieste Trieste Italy
| |
Collapse
|
19
|
Merante S, Ferretti VV, Elena C, Brazzelli V, Zanotti R, Neri I, Magliacane D, Belloni Fortina A, Ingeborg F, Pastorello EA, Pieri L, Papayannidis C, Mauro M, Grifoni F, Minelli R, Guggiari E, Difonzo E, Bocchia M, Caroppo F, Di Nuzzo S, Elli EM, Rondoni M, Ciccocioppo R, Di Stefano M, Bossi G, Boveri E, Bonadonna P, Giona F, Valent P, Triggiani M. The Italian Mastocytosis Registry: 6-year experience from a hospital-based registry. Future Oncol 2018; 14:2713-2723. [DOI: 10.2217/fon-2018-0291] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Aim: We collected ‘real-life’ data on the management of patients with mastocytosis in the Italian Mastocytosis Registry. Methods: Six hundred patients diagnosed with mastocytosis between 1974 and 2014 were included from 19 centers. Results: Among adults (n = 401); 156 (38.9%) patients were diagnosed with systemic mastocytosis. In 212 adults, no bone marrow studies were performed resulting in a provisional diagnosis of mastocytosis of the skin. This diagnosis was most frequently established in nonhematologic centers. In total, 182/184 pediatric patients had cutaneous mastocytosis. We confirmed that in the most patients with systemic mastocytosis, serum tryptase levels were >20 ng/ml and KIT D816V was detectable. Conclusion: The Italian Mastocytosis Registry revealed some center-specific approaches for diagnosis and therapy. Epidemiological evidence on this condition is provided.
Collapse
Affiliation(s)
- Serena Merante
- Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- Hematology Department, James Cook University Hospital, South Tees Trust (NHS), Middlesbrough, UK
| | | | - Chiara Elena
- Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | | | | | - Iria Neri
- Dermatology, Department of Experimental, Diagnostic & Specialty Medicine, University of Bologna, Bologna, Italy
| | | | | | | | | | - Lisa Pieri
- Center of Research & Innovation of Myeloproliferative Neoplasms (CRIMM), Careggi University Hospital/University of Florence, Florence, Italy
| | | | | | - Federica Grifoni
- Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy
| | | | | | - Elisa Difonzo
- Dermatology, University of Florence, Florence, Italy
| | | | | | | | - Elena Maria Elli
- Divisione di Ematologia, Ospedale San Gerardo, ASST Monza, Italy
| | | | - Rachele Ciccocioppo
- Gastroenterology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
| | | | - Grazia Bossi
- Pediatric Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Emanuela Boveri
- Pathology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, University of Pavia, Italy
| | | | - Fiorina Giona
- Ematologia, Sapienza Università di Roma, Azienda Policlinico Umberto I Roma, Italy
| | - Peter Valent
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
- Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria
| | | |
Collapse
|
20
|
Abstract
From its availability for clinical use nearly two decades ago for severe asthma, omalizumab has gained strong evidence of efficacy and safety in the treatment of severe asthma not controlled by standard-of-care therapy. It has been acknowledged by Global Initiative on Asthma guidelines as add-on therapy against severe uncontrolled asthma. Thanks to controlled trials supporting its efficacy, omalizumab has also been licensed for the treatment of chronic spontaneous urticaria. The optimal duration of treatment in either disease has not been established. Despite its high price, omalizumab appears to be cost-effective in severe uncontrolled asthma as well as in chronic urticaria. The literature suggests a wide range of applications for omalizumab in various disorders regardless of allergic or non-allergic pathophysiology.
Collapse
Affiliation(s)
| | - Marina Mauro
- Allergy Department, Sant'Anna Hospital, Como, Italy
| | - Elena Makri
- Cardiac/Pulmonary Rehabilitation, ASST Pini/CTO, Milan, Italy,
| | - Gualtiero Leo
- Pediatric Allergy and Respiratory Pathophysiology Unit, Department of Pediatrics, Vittore Buzzi Children's Hospital, Milan, Italy
| | - Erminia Ridolo
- Department of Medicine and Surgery, University of Parma, Parma, Italy
| |
Collapse
|
21
|
Bilò MB, Pravettoni V, Bignardi D, Bonadonna P, Mauro M, Novembre E, Quercia O, Cilia M, Cortellini G, Costantino MT, Cremonte L, Lodi Rizzini F, Macchia L, Marengo F, Murzilli F, Patella V, Reccardini F, Ricciardi L, Ridolo E, Romano A, Savi E, Schiavino D, Severino M, Pastorello EA. Hymenoptera Venom Allergy: Management of Children and Adults in Clinical Practice. J Investig Allergol Clin Immunol 2018; 29:180-205. [PMID: 30183660 DOI: 10.18176/jiaci.0310] [Citation(s) in RCA: 50] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Hymenoptera venom allergy is an epidemiologically underestimated condition and a major cause of morbidity worldwide. Preventing future allergic reactions in patients who experience a systemic reaction is based on the correct management of the emergency followed by an accurate diagnosis, prescription of adrenaline autoinjectors, and, where indicated, specific venom immunotherapy. Some epidemiological studies highlight our poor knowledge of this disease and the frequent inadequacy of its management. Moreover, they emphasize the importance of such a life-saving treatment as specific immunotherapy. The availability of high-quality hymenoptera venom extracts for diagnostic and therapeutic use has dramatically improved the prognosis and quality of life of allergic patients. Subcutaneous venom immunotherapy is currently the most effective form of allergen-based immunotherapy, with a carry-over effect lasting up to several years after its interruption. This report on the management of hymenoptera venom-allergic children and adults was prepared by a panel of Italian experts. The main objective of this consensus document is to review the scientific evidence related to diagnosis, therapy, and management of patients allergic to hymenoptera venom. Thus, we can improve our knowledge of the disease and promote good clinical practices. The present document provides practical suggestions for correct diagnosis, prescription of emergency therapy and immunotherapy, and strategies for patient care.
Collapse
Affiliation(s)
- M B Bilò
- U.O.C. Allergology, Department of Internal Medicine, University-Hospital Ospedali Riuniti di Ancona, Italy
| | - V Pravettoni
- U.O.C. General Medicine - Immunology and Allergology, Foundation IRCCS Ca´ Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - D Bignardi
- U.O.C. Allergology, Ospedale Policlinico San Martino, Genova, Italy
| | - P Bonadonna
- U.S.D. Allergology, Integrated University-Hospital of Verona, Italy
| | - M Mauro
- U.O.S. Allergology, Hospital S. Anna Como ASST Lariana, Italy
| | - E Novembre
- Complex Organizational Unit of Allergology, University-Hospital A. Meyer, Firenze, Italy
| | - O Quercia
- High Specialization Unit of Allergology, Hospital of Faenza, AUSL (Local Health Unit) of Romagna, Italy
| | - M Cilia
- Allergology Practice, C.d.S. of Scilla, Reggio Calabria, Italy
| | - G Cortellini
- Allergology, O.U. Internal Medicine and Rheumatology, Rimini, Local Health Unit of Romagna, Italy
| | - M T Costantino
- Departmental Structure Day Hospital Center, Allergology and Clinic Immunology Local Health Unit of Mantova, Intercompany Allergology ATS Val Padana, Italy
| | - L Cremonte
- SS Allergologia ASL AL Alessandria, Italy
| | - F Lodi Rizzini
- S.S.V.D. Allergology Civil Hospitals of Brescia, Department of Clinical and Experimental Sciences University of Brescia, Italy
| | - L Macchia
- School and Chair of Allergology and Clinical Immunology, University of Bari, Italy
| | - F Marengo
- Allergology and Clinical Immunology, A.O.U. Città della Salute e della Scienza di Torino
| | - F Murzilli
- U.O.S.D. of Allergology Hospital S.S. Filippo and Nicola, Avezzano (AQ), Italy
| | - V Patella
- Allergy and Clinical Immunology Division, Department of Medicine, Civil Hospital of Battipaglia, Salerno, Italy
| | - F Reccardini
- SOC Pneumology, Respiratory Physiopathology, integrated University Health Authority of Udine, Italy
| | - L Ricciardi
- Allergy and Clinical Immunology Unit - University Hospital AOU Policlinico G.Martino, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
| | - E Ridolo
- Department of Medicine and Surgery, University of Parma, Italy
| | - A Romano
- Unit of Allergology, Presidio Columbus, Rome, Italy
| | - E Savi
- Operating Departmental Unit of Allergology, Hospital G. Da Saliceto, Piacenza, Italy
| | - D Schiavino
- Complex Operating Unit of Allergology, Policlinico Gemelli - School of Specialization in Allergology and Clinical Immunology, Catholic University, Rome, Italy
| | - M Severino
- Allergy Unit, San Giovanni di Dio Hospital, Florence, Italy
| | - E A Pastorello
- Complex Unit of Allergology and Immunology at ASST Grande Ospedale Metropolitano Niguarda - School of Specialization in Allergology and Clinical Immunology at University of Milan, Italy
| |
Collapse
|
22
|
Bonadonna P, Zanotti R, Pagani M, Bonifacio M, Scaffidi L, Olivieri E, Franchini M, Reccardini F, Costantino MT, Roncallo C, Mauro M, Boni E, Rizzini FL, Bilò MB, Marcarelli AR, Passalacqua G. Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected. The Journal of Allergy and Clinical Immunology: In Practice 2018; 6:1368-1372. [DOI: 10.1016/j.jaip.2017.11.025] [Citation(s) in RCA: 37] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/12/2017] [Revised: 11/09/2017] [Accepted: 11/16/2017] [Indexed: 11/15/2022]
|
23
|
Ridolo E, Martignago I, Passalacqua G, Mauro M, Incorvaia C. Evaluation of the safety of a protocol for switching venom immunotherapy products. Ann Allergy Asthma Immunol 2018; 120:429-430. [PMID: 29409970 DOI: 10.1016/j.anai.2018.01.026] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2017] [Revised: 01/15/2018] [Accepted: 01/18/2018] [Indexed: 10/18/2022]
Affiliation(s)
- Erminia Ridolo
- Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy.
| | - Irene Martignago
- Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy
| | | | - Marina Mauro
- Allergy Unit, Sant'Anna Hospitalm ASST Lariana, Como, Italy
| | | |
Collapse
|
24
|
Macchia D, Cortellini G, Mauro M, Meucci E, Quercia O, Manfredi M, Massolo A, Valentini M, Severino M, Passalacqua G. Vespa crabro immunotherapy versus Vespula-venom immunotherapy in Vespa crabro allergy: a comparison study in field re-stings. World Allergy Organ J 2018; 11:3. [PMID: 29441146 PMCID: PMC5797382 DOI: 10.1186/s40413-018-0183-6] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2017] [Accepted: 01/03/2018] [Indexed: 11/25/2022] Open
Abstract
Background In ascertained allergic sensitization to Vespa crabro (VC) venom, the European guidelines still consider venom immunotherapy (VIT) with Vespula (VE) venom sufficient to achieve an adequate protection against VC. However, antigen 5 immunoblotting studies showed that a genuine sensitization to VC venom may exist. In such cases, a specific VC venom would be preferable for VIT treatment. Since in the last few years, VC venom extracts became available for diagnosis and desensitization, we assessed the efficacy and safety of VIT with a VC-VIT, compared to VE extract. Methods Patients stung by VC, and carefully diagnosed for specific sensitization and indication to VIT underwent a 5-year course of immunotherapy with either VE or VC extracts. The severity of reactions at the first sting (pre-VIT) and after field re-stings (during VIT) were compared. Results Eighty-three patients, treated with VE extract and 130 patients treated with VC extract completed the 5-year course of VIT. Only a fraction of those patients (43,8%) were field-re-stung by VC: 64 patients on VC VIT and 69 on VE VIT. In the VC VIT group, reactions at re-sting were: 50 negative, 12 large local reactions, 4 systemic reactions (Muller grade I). In this group the VC VIT efficacy was 93,8%. In the VE VIT treated group the reactions at VC re-sting were: 51 negative, 10 large local reactions and 9 systemic reactions (5 Muller I, 3 Mueller III, 1 Muller IV). In this group the overall efficacy of VIT was 87,0%. The difference in efficacy between the two groups was not statistically significant, as previously reported in literature. Nonetheless, field sting systemic reactions Muller III and IV were recorded only in those patients receiving VE VIT. Conclusion This observation suggests that in patients with ascertained VC-induced allergic reactions a specific VC VIT, where available, would be more adequate, at least concerning the safety profile.
Collapse
Affiliation(s)
- Donatella Macchia
- Allergy and Clinical Immunology Unit, S. Giovanni di Dio Hospital, Florence, Italy
| | | | | | - Elisa Meucci
- Allergy and Clinical Immunology Unit, S. Giovanni di Dio Hospital, Florence, Italy
| | | | - Mariangela Manfredi
- Immunology and Allergy Laboratory, S.Giovanni di Dio Hospital, Florence, Italy
| | - Alessandro Massolo
- 6Department of Biology, University of Pisa, Pisa, Italy.,Laboratoire Chrono-environnement UMR 6249 CNRS, Université Bourgogne Franche-Comté UsC INRA, Besancon, France
| | - Maurizio Valentini
- Immunology and Allergy Laboratory, S.Giovanni di Dio Hospital, Florence, Italy
| | - Maurizio Severino
- Allergy and Clinical Immunology Unit, S. Giovanni di Dio Hospital, Florence, Italy
| | - Giovanni Passalacqua
- 8Allergy and Respiratory Diseases, Policlinico San Martino, University of Genoa, L.Go R. Benzi 10, 16132 Genoa, Italy
| |
Collapse
|
25
|
Losappio LM, Cappai A, Arcolaci A, Badiu I, Bonadonna P, Boni E, Bussolino C, Caminati M, Galati P, Heffler E, Intravaia R, Mauro M, Massaro I, Romano AG, Rumi G, Parolo A, Pizzimenti S, Pastorello EA. Anxiety and depression effects during drug provocation test. J Allergy Clin Immunol 2018. [DOI: 10.1016/j.jaci.2017.12.105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
26
|
Losappio LM, Cappai A, Arcolaci A, Badiu I, Bonadonna P, Boni E, Bussolino C, Caminati M, Galati P, Heffler E, Intravaia R, Mauro M, Massaro I, Romano A, Rumi G, Parolo A, Pizzimenti S, Nichelatti M, Pastorello EA. Anxiety and Depression Effects During Drug Provocation Test. J Allergy Clin Immunol Pract 2018; 6:1637-1641. [PMID: 29339128 DOI: 10.1016/j.jaip.2017.12.005] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 09/14/2017] [Revised: 11/30/2017] [Accepted: 12/11/2017] [Indexed: 11/16/2022]
Abstract
BACKGROUND Drug provocation test (DPT) represents the gold standard for the diagnosis of drug allergy. A DPT can be performed in a single-blind placebo-controlled manner. In anxiety and depressive disorders, patients need to be evaluated to understand the nature of placebo reactions. OBJECTIVE The aim of this study was to evaluate the psychological profile of patients with reactions to placebo during a DPT. METHODS We consecutively enrolled patients with suspected drug allergy undergoing a DPT preceded by the administration of the placebo. All patients underwent the Hospital Anxiety and Depression Scale (HADS), a questionnaire aimed to identify anxiety and depression, before the challenge test. RESULTS A total of 196 patients were enrolled into this study: 8 (4%) patients resulted positive to the DPT, 60 (30.6%) demonstrated anxiety or depression based on the HADS, and 54 had at least 1 placebo reaction during drug provocation. There were statically significant correlations between the positivity of the HADS and the finding of a placebo reaction (Fisher's exact test: P < .001), and between the latter and a history of severe reactions to drug (Fisher's exact test: P < .001). CONCLUSIONS There is a significant and strong correlation between the loss of psychic equilibrium and the development of a placebo reaction during a DPT. We suggest the use the HADS or other validated questionnaire in clinical practice before a DPT to evaluate the possible psychiatric components.
Collapse
Affiliation(s)
| | | | - Alessandra Arcolaci
- Department of Internal Medicine, Allergology and Clinical Immunology, University of Cagliari, Cagliari, Italy
| | - Iuliana Badiu
- Allergy Unit, Santa Croce e Carle Hospital, Cuneo, Italy
| | - Patrizia Bonadonna
- Asthma Center and Allergy Unit, Verona University Hospital, Verona, Italy
| | - Elisa Boni
- Allergy Unit, Santo Spirito Hospital, Casale Monferrato, AL, Italy
| | - Claudia Bussolino
- Allergy and Clinical Immunology Unit, Mauriziano Umberto I Hospital, Torino, Italy
| | - Marco Caminati
- Asthma Center and Allergy Unit, Verona University Hospital, Verona, Italy
| | - Pietro Galati
- Allergy Unit, Sant'Orsola Malpighi Hospital, Bologna, Italy
| | - Enrico Heffler
- Department of Biomedical Sciences-Personalized Medicine, Asthma and Allergy Clinic-Humanitas University and Research Hospital, Milano, Italy
| | | | - Marina Mauro
- Allergy Unit, ASST Lariana, Sant'Anna Hospital, Como, Italy
| | - Ilaria Massaro
- Transfusion Medicine Unit, Careggi Hospital, Firenze, Italy
| | - Antonino Romano
- Allergy Unit, Fondazione Policlinico Universitario A. Gemelli, Sacro Cuore University, Columbus, Roma, Italy
| | - Gabriele Rumi
- Allergy Unit, Fondazione Policlinico Universitario A. Gemelli, Sacro Cuore University, Columbus, Roma, Italy
| | - Anna Parolo
- Inter-departmental, Unit of Transfusion Medicine, Padova, Italy
| | | | | | | |
Collapse
|
27
|
Frati F, Scurati S, Puccinelli P, Morviducci C, Di Cara G, Boccardo R, Piergentili E, Milioni M, Bernardini R, Sambugaro R, Castellano F, Varricchio A, Manfredi G, Cordero L, Russello M, Guercio E, Mauro M, Incorvaia C. Inflammation in Respiratory Allergy Treated by Sublingual Immunotherapy. EUR J INFLAMM 2017. [DOI: 10.1177/1721727x0900700301] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
The most common allergic diseases, such as rhinitis, asthma and atopic dermatitis, are sustained by allergic inflammation, the treatment of which requires anti-inflammatory activity. Among the available treatments, allergen immunotherapy (IT) has a documented impact on allergic inflammation which persists after its discontinuation and modifies the natural course of allergy. The anti-inflammatory effects of IT, and particularly of sublingual IT (SLIT), are based on the ability to modify the phenotype of T cells which, in allergic subjects, are characterized by a prevalence of the Th2 type, with production of IL-4, IL-5, IL-13, IL-17, and IL-32 cytokines. IT-induced changes result in a Th1-type response (immune deviation) related to an increased IFN-gamma and IL-2 production or in a Th2 reduced activity, through a mechanism of anergy or tolerance. It is now known that T cell tolerance is characterized by the generation of allergen-specific Treg cells, which produce cytokines such as IL-10 and TGF-beta with immunosuppressant and/or immunoregulatory activity. Recent studies suggest that the anti-inflammatory mechanism of SLIT is similar to classical, subcutaneous IT, with a prominent role in SLIT for mucosal dendritic cells. The tolerance pattern induced by Treg accounts for the suppressed or reduced activity of inflammatory cells and for the isotypic switch of antibody synthesis from IgE to IgG, and especially to IgG4. Data obtained from biopsies clearly indicate that the pathophysiology of the oral mucosa plays a pivotal role in inducing tolerance to the sublingually administered allergen.
Collapse
Affiliation(s)
- F. Frati
- Pediatrics, University Department of Medical and Surgical Specialty and Public Health, Perugia
- Medical and Scientific Department, Stallergenes, Milan
| | - S. Scurati
- Medical and Scientific Department, Stallergenes, Milan
| | - P. Puccinelli
- Medical and Scientific Department, Stallergenes, Milan
| | | | - G. Di Cara
- Pediatrics, University Department of Medical and Surgical Specialty and Public Health, Perugia
| | - R. Boccardo
- Pediatrics, University Department of Medical and Surgical Specialty and Public Health, Perugia
| | - E. Piergentili
- Pediatrics, University Department of Medical and Surgical Specialty and Public Health, Perugia
| | - M. Milioni
- Pediatrics, University Department of Medical and Surgical Specialty and Public Health, Perugia
| | | | | | | | | | - G. Manfredi
- Clinical Immunology, Miulli Hospital, Acquaviva delle Fonti
| | - L. Cordero
- Pneumology Unit, University Hospital, Sassari
| | | | - E. Guercio
- General Hospital, Castrovillari, Cosenza
| | - M. Mauro
- Allergy Unit, Sant'Anna Hospital, Como
| | - C. Incorvaia
- Allergy/Pulmonary rehabilitation Unit, ICP Hospital, Milan, Italy
| |
Collapse
|
28
|
Abstract
INTRODUCTION Allergy to Hymenoptera (Apis mellifera, Vespula species, Polistes species, Vespa crabro) venom can be safely and effectively treated by venom immunotherapy (VIT), which in the 40 years since its introduction has been able to prevent reactions to stings, and to treatment as well, though systemic reactions, occasionally severe, are possible. Areas covered: We reviewed the recent literature on VIT by searching in PubMed for the terms 'venom immunotherapy' and 'Hymenoptera venom immunotherapy' to highlight the current status of VIT and the likely development in the coming years. Expert commentary: VIT, provided the correct choice of the venom and adequate venom preparations and maintenance doses are used, is a treatment of great value in preventing systemic reactions to Hymenoptera stings. A 5-year duration ensures a prolonged tolerance to stings following VIT discontinuation, unless patients suffer from mastocytosis. In fact, due to reports of fatal reactions after stopping VIT, patients with mastocytosis, or with very severe reactions to stings, need an indefinite duration of treatment.
Collapse
Affiliation(s)
| | - Marina Mauro
- b Department of Clinical & Experimental Medicine , University of Parma , Parma , Italy
| | - Bruna L Gritti
- a Cardiac/Pulmonary Rehabilitation , ASST Pini/CTO , Milan , Italy
| | - Eleni Makri
- a Cardiac/Pulmonary Rehabilitation , ASST Pini/CTO , Milan , Italy
| | - Erminia Ridolo
- c Allergy Unit , Sant'Anna Hospital, ASST Lariana , Como , Italy
| |
Collapse
|
29
|
Abstract
Apple allergy is common in patients allergic to birch pollen, and this is defined as ‘birch-apple syndrome’. Allergens responsible for cross-reactivity belong to the pathogenesis-related-10 family, and high homology in the amino acid sequences of the major allergens Bet v 1 from birch and Mal d 1 from apple has been demonstrated. Here we review the literature on the treatment of birch-apple syndrome by allergen immunotherapy. The only allergen immunotherapy method available thus far is based on the administration of birch-pollen extracts, through the subcutaneous or sublingual route, to induce tolerance to Bet v1 and to the homologous allergen Mal d 1. However, the studies performed thus far show modest efficacy, and thus other methods of immunotherapy should be investigated.
Collapse
Affiliation(s)
| | - Erminia Ridolo
- Department of Clinical & Experimental Medicine, University of Parma, Via Gramsci 14, Parma, Italy
| | - Marina Mauro
- Allergy Unit, Sant’Anna Hospital, ASST Lariana, Como, Italy
| | | | - Elide Pastorello
- Unit of Allergology & Immunology, Niguarda Ca’ Granda Hospital, Milan, Italy
| |
Collapse
|
30
|
Coppel R, Gomez AL, Finet G, Mauro M, Pettigrew RI, Ohayon J, Lagache M. Experimental Bench for Hemodynamic Study of Coronary Artery with Serial Stenoses: Fractional Flow Reserve Assessment. Comput Methods Biomech Biomed Engin 2017; 20:45-46. [PMID: 29088640 DOI: 10.1080/10255842.2017.1382853] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- R Coppel
- a Laboratory TIMC-IMAG/DyCTiM2 , UJF, CNRS UMR 5525 , Grenoble , France
| | - A L Gomez
- a Laboratory TIMC-IMAG/DyCTiM2 , UJF, CNRS UMR 5525 , Grenoble , France
| | - G Finet
- b Department of Hemodynamics and Interventional Cardiology , Hospices Civils de Lyon and Claude Bernard University Lyon1, INSERM Unit 886 , Lyon , France
| | - M Mauro
- c Department of Mechanical Engineering, Energetics and Materials , Public University of Navarra , Pamplona , Spain
| | - R I Pettigrew
- d Laboratory of Integrative Cardiovascular Imaging Science , National Institute of Diabetes Digestive and Kidney Diseases, National Institutes of Health , Bethesda , MD , USA
| | - J Ohayon
- a Laboratory TIMC-IMAG/DyCTiM2 , UJF, CNRS UMR 5525 , Grenoble , France.,e University of Savoie Mont-Blanc, Polytech Annecy-Chambéry , Le Bourget du Lac , France
| | - M Lagache
- e University of Savoie Mont-Blanc, Polytech Annecy-Chambéry , Le Bourget du Lac , France.,f Laboratory SYMME , Chambéry , France
| |
Collapse
|
31
|
Savi E, Incorvaia C, Boni E, Mauro M, Peveri S, Pravettoni V, Quercia O, Reccardini F, Montagni M, Pessina L, Ridolo E. Which immunotherapy product is better for patients allergic to Polistes venom? A laboratory and clinical study. PLoS One 2017; 12:e0180270. [PMID: 28686638 PMCID: PMC5501507 DOI: 10.1371/journal.pone.0180270] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2016] [Accepted: 06/13/2017] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND Venom immunotherapy (VIT) is highly effective in preventing allergic reactions to insect stings, but the appropriate venom must be used to achieve clinical protection. In patients with multiple positive results to venoms, molecular allergy diagnostics or CAP-inhibition may identify the causative venom. Concerning allergy to venom from Polistes spp. it has been proposed that only the European species P. dominulus should be used for VIT. However, this recommendation is not present in any international guideline. Using both laboratory and clinical data, we aimed to evaluate the reliability of this proposal. METHODS We performed an in vitro study using CAP-inhibition to determine sensitization of 19 patients allergic to Polistes venom. The clinical study included 191 patients with positive tests to Polistes treated with VIT, 102 were treated with P. dominulus and 89 were treated with a mix of American Polistes (mAP). RESULTS The difference in % of inhibition was significant concerning inhibition of P. dominulus sIgE by P. dominulus venom (79.8%) compared with inhibition by mAP venom (64.2%) and not significant concerning the inhibition of mAP sIgE by P. dominulus venom (80.1%) and by mAP venom (73.6%). Instead, the clinical protection from stings was not statistically different between the two kinds of venom. CONCLUSION The data from CAP inhibition would suggest that the choice of either P. dominulus venom or mAP venom for VIT is appropriate in patients with CAP inhibition higher than 70%, but the clinical data show the same odds of protection from stings using for VIT P. dominulus or mAP venom.
Collapse
Affiliation(s)
- Eleonora Savi
- Allergy Dept. Unit, G. Da Saliceto Hospital, AUSL, Piacenza, Italy
| | | | - Elisa Boni
- Allergy Unit, Sant’Anna Hospital, ASST Lariana, Como, Italy
| | - Marina Mauro
- Allergy Unit, Sant’Anna Hospital, ASST Lariana, Como, Italy
| | - Silvia Peveri
- Allergy Dept. Unit, G. Da Saliceto Hospital, AUSL, Piacenza, Italy
| | - Valerio Pravettoni
- Clinical Allergy and Immunology Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - Oliviero Quercia
- Unità ad Alta Specializzazione di Allergologia, Ospedale di Faenza (RA), Faenza, Italy
| | - Federico Reccardini
- Azienda Sanitaria Universitaria Integrata Udine, SOC Pneumologia Fisiopatologia Respiratoria, Udine, Italy
| | | | - Laura Pessina
- Cardiac/Pulmonary Rehabilitation, ASST Gaetano Pini/CTO, Milan, Italy
| | - Erminia Ridolo
- Department of Medicine and Surgery, University of Parma, Parma, Italy
- * E-mail:
| |
Collapse
|
32
|
Larese Filon F, Plazzotta S, Rui F, Mauro M, De Michieli P, Negro C. Ten-year incidence of contact dermatitis in a prospective cohort of healthcare workers in Trieste hospitals (North East of Italy) 2004-2013. Br J Dermatol 2017; 177:560-561. [PMID: 27718523 DOI: 10.1111/bjd.15118] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- F Larese Filon
- Unità Clinico Operativa di Medicina del Lavoro, Dipartimento di Scienze di Medicina Pubblica, Università degli Studi di Trieste, Via della Pietà, 19-24120, Trieste, Italy
| | - S Plazzotta
- Unità Clinico Operativa di Medicina del Lavoro, Dipartimento di Scienze di Medicina Pubblica, Università degli Studi di Trieste, Via della Pietà, 19-24120, Trieste, Italy
| | - F Rui
- Unità Clinico Operativa di Medicina del Lavoro, Dipartimento di Scienze di Medicina Pubblica, Università degli Studi di Trieste, Via della Pietà, 19-24120, Trieste, Italy
| | - M Mauro
- Unità Clinico Operativa di Medicina del Lavoro, Dipartimento di Scienze di Medicina Pubblica, Università degli Studi di Trieste, Via della Pietà, 19-24120, Trieste, Italy
| | - P De Michieli
- Unità Clinico Operativa di Medicina del Lavoro, Dipartimento di Scienze di Medicina Pubblica, Università degli Studi di Trieste, Via della Pietà, 19-24120, Trieste, Italy
| | - C Negro
- Unità Clinico Operativa di Medicina del Lavoro, Dipartimento di Scienze di Medicina Pubblica, Università degli Studi di Trieste, Via della Pietà, 19-24120, Trieste, Italy
| |
Collapse
|
33
|
Parisi MG, Mauro M, Sarà G, Cammarata M. Temperature increases, hypoxia, and changes in food availability affect immunological biomarkers in the marine mussel Mytilus galloprovincialis. J Comp Physiol B 2017; 187:1117-1126. [PMID: 28389696 DOI: 10.1007/s00360-017-1089-2] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2016] [Revised: 03/01/2017] [Accepted: 03/15/2017] [Indexed: 01/06/2023]
Abstract
Temperature increases, hypoxia, and changes in food availability are predicted to occur in the future. There is growing concern for the health status of wild and farmed organisms, since environmental stressors alter organism functions, and elicit coordinated physiological responses for homeostasis. Mussels are good bioindicators of environmental conditions. Their ability to maintain unaltered immunosurveillance under adverse environmental conditions may enhance their survival capability. Few studies are currently concerned with the relationships and feedback among multiple stressors. Here, food concentration, temperature, and oxygenation treatments were evaluated for their effects on immune enzymatic parameters of Mytilus galloprovincialis detected in the digestive gland and the lysosomal viability by neutral red uptake. Mussels were exposed to three temperatures (12, 20, and 28 °C) under normoxic (8 mg O2l-1) and anoxic conditions and specimens were fed with six food concentrations, ranging 0.2-5 g chlorophyll l-1. Temperature increases affected esterase and alkaline phophatase enzyme functionality, and addition of food buffered detrimental effects generated by harsh conditions, such as those provided by low oxygen concentrations. Kinetics of the phenoloxidase was negatively correlated with increasing temperature. In this case, food had a buffering effect that counteracted the limiting temperature only under normoxic conditions. In addition, the stability of the lysosomal membrane was altered under conditions of thermal stress and food change, under normoxic and anoxic conditions. Overall, environmental stress factors affected immune biomarkers of Mediterranean mussels, and the level of food acted as a buffer, increasing the thermal resistance of the specimens.
Collapse
Affiliation(s)
- M G Parisi
- Marine Immunobiology laboratory, University of Palermo, CONISMA, Via Archirafi 18, 90128, Palermo, Italy.
| | - M Mauro
- Marine Immunobiology laboratory, University of Palermo, CONISMA, Via Archirafi 18, 90128, Palermo, Italy
| | - G Sarà
- Dipartimento di Scienze della Terra e del Mare, University of Palermo, Viale delle Scienze Ed. 16, 90128, Palermo, Italy
| | - M Cammarata
- Marine Immunobiology laboratory, University of Palermo, CONISMA, Via Archirafi 18, 90128, Palermo, Italy
| |
Collapse
|
34
|
Bonadonna P, Passalacqua G, Reccardini F, Rizzini FL, Mauro M, Franchini M, Pagani M, Roncallo C, Costantino MT, Zanotti R. Severe Anaphylactic Reactions after Stopping Hymenoptera Venom Immunotherapy. a Clonal Mast Cell Disorder Should be Suspected. J Allergy Clin Immunol 2017. [DOI: 10.1016/j.jaci.2016.12.738] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
35
|
Bercik P, Schlageter V, Mauro M, Rawlinson J, Kucera P, Armstrong D. Noninvasive Verification of Nasogastric Tube Placement Using a Magnet-Tracking System: A Pilot Study in Healthy Subjects. JPEN J Parenter Enteral Nutr 2017; 29:305-10. [PMID: 15961688 DOI: 10.1177/0148607105029004305] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Fluoroscopic verification of nasogastric (NG) feeding tube placement is inconvenient and involves radiation exposure. We tested whether the position of an NG tube can be assessed reliably by a recently introduced magnet-tracking system. METHODS A small permanent magnet was attached at the end of an NG tube and its position was monitored using an external sensor array connected to a computer. NG tube trajectory, spontaneous movements of the magnet, and its position relative to the lower esophageal sphincter (LES) and xiphisternum were assessed in 22 healthy subjects and compared with esophageal manometry. In 12 subjects, localization of the magnet was also compared with fluoroscopy. RESULTS Magnet-tracking displayed NG tube tip movement reproducibly as it moved vertically in the esophagus and then laterally into the stomach. Compared with manometry, the accuracy and sensitivity of magnet tracking for localization of the NG tube tip, above or below the diaphragm, were 100%. Compared with fluoroscopy, the accuracy of NG tube localization by magnet tracking was 100%. With the magnet in the stomach, but not in the esophagus or LES, low amplitude displacements at a frequency of 3 per minute, consistent with gastric slow wave activity, were observed. CONCLUSIONS Magnet tracking allows accurate, real-time, 3-dimensional localization of an NG tube with respect to anatomic landmarks. Recorded motor patterns are indicative of the position of the NG tube. Magnet tracking may be a useful tool for bedside placement of nasogastric and enteral feeding tubes.
Collapse
Affiliation(s)
- Premysl Bercik
- Division of Gastroenterology and Intestinal Disease Research Program, McMaster University Medical Center, Hamilton, Ontario, Canada
| | | | | | | | | | | |
Collapse
|
36
|
Boni E, Incorvaia C, Mauro M. Dose-dependence of protection from systemic reactions to venom immunotherapy by omalizumab. Clin Mol Allergy 2016; 14:14. [PMID: 27799850 PMCID: PMC5078942 DOI: 10.1186/s12948-016-0051-2] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2016] [Accepted: 10/16/2016] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Systemic reactions (SR) to venom immunotherapy (VIT) are rare but may occur, with a rate significantly higher for honeybee than for vespid VIT. In patients with repeated SRs to VIT it is difficult to reach the maintenance dose of venom and pre-treatment with omalizumab is indicated, as shown by some studies reporting its preventative capacity, when antihistamines and corticosteroids are ineffective. CASE PRESENTATION We present the case of a 47 years old woman allergic to bee venom who experienced two severe SRs after bee stings and several SRs to VIT with bee venom. Pre-treatment with antihistamines and corticosteroids as well as omalizumab at doses up to 300 mg was unsuccessful, while an omalizumab dose of 450 mg finally achieved in our patient the protection from SRs to VIT with 200 mcg of bee venom. CONCLUSIONS The search of the dose of omalizumab able to protect a patient with repeated SRs to VIT may be demanding, but this search is warranted by the need to provide to this kind of patient, by an adequate VIT, the protection from potentially life-threatening reactions.
Collapse
Affiliation(s)
- Elisa Boni
- Allergy Unit, Sant'Anna Hospital, ASST Lariana, Via Napoleona 60, 22100 Como, Italy
| | - Cristoforo Incorvaia
- Allergy/Cardiac and Pulmonary Rehabilitation ASST G. Pini/CTO, Via Bignami 1, 20126 Milan, Italy
| | - Marina Mauro
- Allergy Unit, Sant'Anna Hospital, ASST Lariana, Via Napoleona 60, 22100 Como, Italy
| |
Collapse
|
37
|
Mauro M, De Giusti V, Bovenzi M, Larese Filon F. Effectiveness of a secondary prevention protocol for occupational contact dermatitis. J Eur Acad Dermatol Venereol 2016; 31:656-663. [DOI: 10.1111/jdv.13947] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2016] [Accepted: 07/18/2016] [Indexed: 01/20/2023]
Affiliation(s)
- M. Mauro
- Clinical Unit of Occupational Medicine; Department of Medical Sciences; University of Trieste; Trieste Italy
| | - V. De Giusti
- Clinical Unit of Occupational Medicine; Department of Medical Sciences; University of Trieste; Trieste Italy
| | - M. Bovenzi
- Clinical Unit of Occupational Medicine; Department of Medical Sciences; University of Trieste; Trieste Italy
| | - F. Larese Filon
- Clinical Unit of Occupational Medicine; Department of Medical Sciences; University of Trieste; Trieste Italy
| |
Collapse
|
38
|
Elera JD, Boteanu C, Blanco MAJ, Gonzalez-Mendiola R, García IC, Alvarez A, Martinez JJL, Garrido JM, Barona CT, Chorda CP, Salgueiro RL, Palacios MD, De Rojas DHF, Acar EA, Aktas A, Ermertcan AT, Temiz P, Lin CY, Hui CYR, Chang YC, Yang CH, Chung WH, Carolino F, Silva D, De Castro ED, Cernadas JR, Ensina LF, Aranda C, Nunes IC, Lacerda A, Martins AM, Goudouris E, Ribeiro M, Da Silva Franco JF, Queiroz L, Solé D, Dalgiç CT, Sin AZ, Günsen FD, Bulut G, Ardeniz FÖ, Gülbahar O, Gökmen ENM, Kokuludag A, De Francisco AMM, De Vicente Jiménez TM, Mendoza Parra AM, Burgos Pimentel AM, Luque AG, Amaral L, Leão LC, Pinto N, Belo J, Marques J, Carreiro-Martins P, Leiria-Pinto P, Chaabane A, Romdhane HB, Fredj NB, Chadly Z, Boughattas NA, Aouam K, Uyttebroek AP, Bridts CH, Romano A, Ebo DG, Sabato V, Lopes A, Cosme J, Aguiar R, Lourenço T, Paes MJ, Spínola-Santos A, Pereira-Barbosa M, Cruz CR, Dos Reis RP, Tomaz E, Pires AP, Inácio F, Benito-Garcia F, Mota I, Correia M, Gaspar Â, Chambel M, Piedade S, Morais-Almeida M, Nakonechna A, Antipkin Y, Umanets T, Pineda F, Arribas F, Lapshyn V, Miranda PA, De La Cruz Hoyos B, Blanco AJ, Del Pozo M, Vultaggio A, Nencini F, Pratesi S, Matucci A, Maggi E, Cegec I, Nahal DJ, Turk VE, Aumiler MR, Ausperger KM, Kraljickovic I, Simic I, Yamaguchi Y, Watanabe T, Satoh M, Tanegashima T, Oda K, Wada H, Aihara M, Lee JJ, Choi JC, Lee HY, Fernandes RAR, Faria E, Pita J, Sousa N, Ribeiro C, Carrapatoso I, Bom AT, Rodolfo A, Dias-Castro E, Voronova M, Valle DK, Coronel VP, Chordá CP, Madamba RCY, Ferrer M, Goikoetxea MJ, D’Amelio C, Bernad A, Vega O, Gastaminza G, Bibián BP, Salazar ML, Vilà-Nadal G, Roman AMF, Ortega JD, Muñoz MG, Gancedo SQ, Moreno MRC, Hofmeier KS, Barzylovych V, Pola B, Lluncor M, Fiandor A, Bellón T, Domínguez J, Quirce S, Yang MS, Kim SS, Kim SH, Kang HR, Park HW, Cho SH, Min KU, Chang YS, Delahaye C, Flabbee J, Waton J, Bauvin O, Barbaud A, Fadhel NB, Gulin SJ, Chiriac A, Cardoso BK, Viseu R, Moreira A, Cadinha S, Neves AC, Barreira P, Malheiro D, Da Silva JPM, Jurakic-Toncic R, Ljubojevic S, Turcic P, Gilissen L, Huygens S, Goossens A, Andreu I, Romero AM, Cabezas PG, Parejo PA, Del Carmen Plaza-Serón M, Doña I, Blanca-López N, Flores C, Galindo ML, Molina A, Perkins JR, Cornejo-García JA, García-Agúndez JA, García-Martín E, Campo P, Canto MG, Blanca M, Guéant-Rodríguez RM, Jurado-Escobar R, Barrionuevo E, Salas M, Canto G, Guéant JL, Usui T, Tailor A, Faulkner L, Farrell J, Alfirevic A, Kevin Park B, Naisbitt DJ, Trelles O, Guerrero MA, Upton A, Ueta M, Sawai H, Sotozono C, Tokunaga K, Kinoshita S, Sukasem C, Satapornpong P, Tempark T, Rerknimitr P, Pairayayutakul K, Klaewsongkram J, Koomdee N, Jantararoungtong T, Santon S, Puangpetch A, Intusoma U, Tassaneeyakul W, Theeramoke V, Ramirez E, Borobia AM, Tong H, Castañer JL, De Abajo FJ, Galvao VR, Pavlos R, Mckinnon E, Williams K, Beeghly-Fadiel A, Redwood A, Phillips E, Castells M, Boni E, Russello M, Mauro M, Ue KL, Rutkowski K, Gomis VS, Ferre JF, Rodriguez AE, Reig VC, Sanchez JF, Breynaert C, Van Hoeyveld E, Schrijvers R, Blanco AJ, Irigoyen RF, Collado D, Vida Y, Najera F, Perez-Inestrosa E, Mesa-Antunez P, Mayorga C, Torres MJ, Tannert LK, Mortz CG, Skov PS, Bindslev-Jensen C, Pfützner W, Dörnbach H, Visse J, Rauber M, Möbs C, Elzagallaai AA, Chow L, Abuzgaia AM, Rieder MJ, Trubiano J, Woolnough E, Stautins K, Cheng C, Kato K, Azukizawa H, Hanafusa T, Katayama I, Fujiyama T, Hashizume H, Umayahara T, Ito T, Tokura Y, Silar M, Zidarn M, Rupnik H, Korosec P, Redwood AJ, Strautins K, White K, Chopra A, Konvinse K, Leary S, Mallal S, Cabañas R, Fiandor AM, Sullivan A, Whitaker P, Peckham D, Haw WY, Polak ME, Mcguire C, Ardern-Jones MR, Aoyama Y, Shiohara T, Correia S, Gelincik A, Demir S, Sen F, Bozbey HU, Olgac M, Unal D, Coskun R, Colakoglu B, Buyuozturk S, Çatin-Aktas E, Deniz G, Laguna JJ, Dionicio J, Fernandez T, Olazabal I, Ruiz MD, Torres MJ, Lafuente A, Núñez J, Fernández TD, Palomares F, Fernández R, Sanchez MI, Fernandez T, Ruiz A, Ariza A, Alonso AB, Garófalo CD, Matute OV, Puga MF, Lapresa MJG, Lasarte GG, Thinnes A, Merk HF, Baron JM, Leverkus M, Balakirski G, Gibson A, Ogese M, Al-Attar Z, Yaseen F, Meng X, Jenkins R, Farrel J, Alhilali K, Xue Y, Illing P, Mifsud N, Fettke H, Lai J, Ho R, Kwan P, Purcell A, Ogese MO, Betts C, Thomson P, Alhaidari M, Berry N, O’Neill PM, Alzahrani A, Azoury ME, Fili L, Bechara R, Scornet N, Nhim C, Weaver R, Claude N, Joseph D, Maillere B, Parronchi P, Pallardy M, Villani AP, Rozières A, Bensaïd B, Tardieu M, Albert F, Mutez V, Baysal T, Maryanski J, Nicolas JF, Kanagawa O, Vocanson M, Hung SI, Harrison CJ, Jenkins RE, French NS, Montañez MI, Fernandez TD, Martin-Serrano A, Torres MJ, Molina N, Wood S, Pirmohamed M, Montañez MI, Martín-Serrano Á, Pérez-Inestrosa E, Pérez-Sala D, Guzmán AE, Ko TM, Chen YT, Wu JY, Sánchez-Gómez FJ, González-Morena JM, Torres MJ, Arreola AM, Corona JAB, Flores SM, Cherit JD, Figueroa NVD, Flores JLC, Perkins J, Pérez-Alzate D, Bogas G, Torres MJ, Marti LMT, De La Losa FP, Poves FA, Lopez JT, Santiago TL. 7th Drug hypersensitivity meeting: part two. Clin Transl Allergy 2016. [PMCID: PMC5009521 DOI: 10.1186/s13601-016-0122-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
39
|
Carr DF, Chung WH, Jenkiins RE, Chaponda M, Nwikue G, Cornejo Castro EM, Antoine DJ, Pirmohamed M, Wuillemin N, Dina D, Eriksson KK, Yerly D, Pavlos R, Mckinnin E, Ostrov D, Peters B, Buus S, Koelle D, Chopra A, Rive C, Redwood A, Restrepo S, Bracey A, Yuan J, Gaudieri S, Carrington M, Haas D, Mallal S, Phillips E, De Boer D, Menheere P, Nieuwhof C, Bons J, Jonsson F, De Chaisemartin L, Granger V, Gillis C, Gouel A, Neukirch C, Dib F, Nicaise PR, Longrois D, Tubach F, Martin S, Bruhns P, Chen KL, Liao SL, Sheen YS, Cho YT, Yang CW, Liau JY, Chu CY, Aguiar R, Lopes A, Fernandes N, Viegas L, Pereira-Barbosa MA, Bünter A, Gupta N, Petkovic TP, Wirth N, Pichler WJ, Hausmann O, Yazicioglu M, Ozdemir PG, Ciplak G, Kaya O, Cooke PJ, Mota I, Gaspar Â, Benito-Garcia F, Chambel M, Morais-Almeida M, Marques L, Alcoceba E, Lara S, Carneiro-Leão L, Botelho C, Dias-Castro E, Cernadas JR, Nicholls K, Lay W, Smith O, Collins C, Unglik G, Spriggs K, Auyeung P, McComish J, Douglass JA, Peter JG, Potter P, Carolino F, De Castro ED, Moreira AS, Abreu C, Gomes E, Cardoso BK, Tomaz E, Correia S, Inácio F, Arnold A, Bear N, Rueter K, Gong G, O’Sullivan M, Muthusamy S, Noble V, Lucas M, Buterleviciute N, Rudzeviciene O, Abreu C, May S, Pongdee T, Park M, Griguola L, Vinikovas A, Kašinskaite S, Kvedariene V, Aktas A, Rahman S, Elbi H, Ozyurt BC, Cavkaytar O, Karaatmaca B, Cetinkaya PG, Esenboga S, Sahiner UM, Sekerel BE, Soyer O, Zubrinich C, Tong B, Patel M, Giles M, O’Hehir R, Puy R, Amaral L, Demir S, Gelincik A, Olgac M, Caskun R, Unal D, Colakoglu B, Buyukozturk S, Matute OV, Bernad A, Gastaminza G, Madamba R, Lacasa C, Goikoetxea MJ, D’Amelio C, Rifón J, Martínez N, Ferrer M, Ribeiro C, Faria E, Frutuoso C, Barros A, Lebre R, Pego A, Bom AT, Ensina LF, Aranda C, Nunes IC, Martins AM, Solé D, Bavbek S, Kendirlinan R, Çerçi P, Tutluer S, Soyyigit S, Sözener ZÇ, Aydin Ö, Gümüsburun R, Almeida M, Sai K, Imatoh T, Nakamura R, Fukazawa C, Hinomura Y, Saito Y, Sousa-Pinto B, Correia C, Gomes L, Gil-Mata S, Araújo L, Delgado L, Sai K, Okamoto-Uchida Y, Kajinami K, Matsunaga K, Aihara M, Wang CW, Su SC, Hung SI, Ho HC, Yang CH, Paulmann M, Dunant A, Mockenhaupt M, Sekula P, Schumacher M, Kardaun S, Naldi L, Bellón T, Creamer D, Haddad C, Sassolas B, Lebrun-Vignes B, Valeyrie-Allanore L, Roujeau JC, Paulmann M, Kremmler C, Mockenhaupt M, Dodiuk-Gad RP, Olteanu C, Feinstein A, Hashimoto R, Alhusayen R, Whyte-Croasdaile S, Finkelstein Y, Burnett M, Sade S, Cartotto R, Jeschke M, Shear NH, Takamura N, Yamane Y, Matsukura S, Nakamura K, Watanabe Y, Yamaguchi Y, Kambara T, Ikezawa Z, Aihara M, Hashimoto R, Chew H, Burnett M, Jeschke M, Knezevic B, Ionmhain UN, Barraclough A, Anstey M, Usui T, Meng X, Farrell J, Whitaker P, Watson J, French N, Park K, Naisbitt D, Neves AC, Cadinha S, Moreira A, Da Silva JPM, Drvar DL, Gulin SJ, Hadzavdic SL, Ceovic R, De Francisco AM, De Vicente Jiménez T, Luque AG, David NR, Galván JMM, Darlenski R, Gulin D, Sikic J, Habek JC, Galic E, Specht P, Staab D, Mayer B, Roehmel J, Solovan C, Chiriac A, Djurinec P, Kostovic K, Bradamante M, Almeida JP, Caiado J, Pedro E, Da Silva PC, Barbosa MP, Bogas G, Blanca-López N, Pérez-Alzate D, Doña I, Agúndez JA, García-Martín E, Cornejo-García JA, Mayorga C, Torres MJ, Canto MG, Blanca M, Aksakal S, Sin AZ, Koç ZP, Günsen FD, Ardeniz Ö, Gökmen ENM, Gülbahar O, Kokuludag A, Pérez-Sánchez N, Salas M, Salas M, Gomez F, Barrionuevo E, Andreu I, Miranda MÁ, Didžiokaite G, Gaidej O, Kašinskaite S, Garcimartin MI, Somoza ML, Bojas G, Cornejo-Garcia JA, Perez FJR, Miranda MA, Jerschow E, Pelletier T, Ren Z, Hudes G, Sanak M, Morales E, Schuster V, Spivack SD, Rosenstreich D, Erzen R, Silar M, Bajrovic N, Rijavec M, Zidarn M, Korosec P, Castro E, Al-Ahmad M, Rodriguez T, Azevedo JP, Tavares B, Regateiro F, Todo-Bom A, Miranda PA, De La Cruz Hoyos B, Abuzeid W, Akbar N, Gibber M, Fried M, Han W, Keskin T, Tamayev R, Spivack SD, Rosenstreich D, Jerschow E, Boni E, Russello M, Mauro M, Neto MF, Brosseron L, Malheiro D, Barreira P, Sprigg D, Trevenen M, Seet J, Trubiano J, Smith W, Jeelall Y, Vale S, Loh R, Mclean-Tooke A, Müller S, Amstutz U, Jörg L, Yawalkar N, Krähenbühl S, Leblanc A, Ribeiro L, Vega A, Rivas RG, Alonso A, Beitia JM, Mateo B, Cárdenas R, Garcia-Dominguez JJ, Pavlos R, Strautins K, James I, Mallal S, Redwood A, Aguiar R, Lopes A, Neves A, Do Céu Machado M, Dalgiç CT, Gökmen ENM, Bulut G, Ardeniz FÖ, Gülbahar O, Sin AZ, Hsu SH, Yang CW, Ye YM, Hur GY, Park HS, Kim SH, Ali S, Hollingsworth PN, Mclean-Tooke APC, Chadly Z, Fredj NB, Aouam K, Romdhane HB, Boughattas NA, Chaabane A, Salazar ML, Pola B, Fiandor A, Ramírez E, Ortega JD, Quirce S, Cabañas R, Baynova K, Labella M, Prados M, Ramonaite A, Bajoriuniene I, Sitkauskiene B, Sakalauskas R, Kwon JW, Park S, Silva D, Leão LC, Castro E, Garcimartin M, De La Torre MV, Pérez FJR, Haroun E, Diez GC, Ónodi-Nagy K, Kinyó Á, Kemény L, Bata-Csörgo Z, Pita JS, Fernandes RA, Moura A, Sousa N, Loureiro C, Pfützner W, Marrouche N, Grattan C, Chen YE, Chen CB, Hsiao YP, Garcimartin MI, Ruano FJ. 7th drug hypersensitivity meeting: part one. Clin Transl Allergy 2016. [PMCID: PMC5009634 DOI: 10.1186/s13601-016-0121-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
Abstract
Oral Abstracts O1 Functionally distinct HMGB1 isoforms correlate with physiological processes in drug-induced SJS/TEN Daniel F. Carr, Wen-Hung Chung, Rosalind E. Jenkiins, Mas Chaponda, Gospel Nwikue, Elena M. Cornejo Castro, Daniel J. Antoine, Munir Pirmohamed O2 Hypersensitivity reactions to beta-lactams, does the t cell recognition pattern influence the clinical picture? Natascha Wuillemin, Dolores Dina, Klara K. Eriksson, Daniel Yerly O3 Specific binding characteristics of HLA alleles associated with nevirapine hypersensitivity Rebecca Pavlos, Elizabeth Mckinnin, David Ostrov, Bjoern Peters, Soren Buus, David Koelle, Abha Chopra, Craig Rive, Alec Redwood, Susana Restrepo, Austin Bracey, Jing Yuan, Silvana Gaudieri, Mary Carrington, David Haas, Simon Mallal, Elizabeth Phillips O4 Do we need to measure total ige for the interpretation of analytical results of ImmunoCAP dnd 3gAllergy specific IgE? Douwe De Boer, Paul Menheere, Chris Nieuwhof, Judith Bons O5 Neutrophil activation in systemic anaphylaxis: results from the multicentric NASA study Friederike Jonsson, Luc De Chaisemartin, Vanessa Granger, Caitlin Gillis, Aurelie Gouel, Catherine Neukirch, Fadia Dib, Pascale Roland Nicaise, Dan Longrois, Florence Tubach, Sylvie Martin, Pierre Bruhns, NASA Study Group O6 Purpuric drug eruptions due to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for non-small-cell lung cancer (NSCLC): a clinic-pathological study of 32 cases Kai-Lung Chen, Shu-Ling Liao, Yi-Shuan Sheen, Yung-Tsu Cho, Che-Wen Yang, Jau-Yu Liau, Chia-Yu Chu Poster presentations: Poster Walk 1—Anaphylaxis (P01–P09) P1 Anaphylactic reactions during anaesthesia and the perioperative period Rita Aguiar, Anabela Lopes, Natália Fernandes, Leonor Viegas, M. A. Pereira-Barbosa P2 Anaphylaxis to chlorhexidine: is there a cross-reactivity to alexidine? Antonia Bünter, Nisha Gupta, Tatjana Pecaric Petkovic, Nicole Wirth, Werner J. Pichler, Oliver Hausmann P3 Cefotaxime-induced severe anaphylaxis in a neonate Mehtap Yazicioglu, Pinar G. Ozdemir, Gokce Ciplak, Ozkan Kaya P4 Clinical features and diagnosis of anaphylaxis resulting from exposure to chlorhexidine Peter John Cooke P5 Drug-induced anaphylaxis: five-year single-center survey Inês Mota, Ângela Gaspar, Filipe Benito-Garcia, Marta Chambel, Mário Morais-Almeida P6 Intraoperative severe anaphylactic reaction due to patent blue v dye Luis Marques, Eva Alcoceba, Silvia Lara P7 Kounis syndrome in the setting of anaphylaxis to diclofenac Leonor Carneiro-Leão, Carmen Botelho, Eunice Dias-Castro, Josefina Cernadas P8 Perioperative anaphylaxis audit: Royal Melbourne Hospital Katherine Nicholls, William Lay, Olivia Smith, Christine Collins, Gary Unglik, Kymble Spriggs, Priscilla Auyeung, Jeremy McComish, Jo A. Douglass P9 Recurrent peri-operative anaphylaxis: a perfect storm Jonny G. Peter, Paul Potter Poster Walk 2: DH regions and patient groups (P10–P19) P10 A rare presentation of amoxicillin allergy in a young child Fabrícia Carolino, Eunice Dias De Castro, Josefina R. Cernadas P11 Adverse drug reactions in children: antibiotics or virus? Ana Sofia Moreira, Carmo Abreu, Eva Gomes P12 Allergic reactions in invasive medical procedures Bárbara Kong Cardoso, Elza Tomaz, Sara Correia, Filipe Inácio P13 Antibiotic allergy in children: room for improvement Annabelle Arnold, Natasha Bear, Kristina Rueter, Grace Gong, Michael O’Sullivan, Saravanan Muthusamy, Valerie Noble, Michaela Lucas P14 Drug hypersensitivity reactions in children and results of diagnostic evaluation Neringa Buterleviciute, Odilija Rudzeviciene P15 Nonimmediate cutaneous drug reactions in children: are skin tests required? Ana Sofia Moreira, Carmo Abreu, Eva Gomes P16 Pediatric patients with a history of penicillin allergy and a positive penicillin skin test may not be at an increased risk for multiple drug allergies Sara May, Thanai Pongdee, Miguel Park P17 Proved hypersensitivity to drugs according data of Vilnius University Hospital Santariskiu Klinikos Linas Griguola, Arturas Vinikovas, Simona Kašinskaite, Violeta Kvedariene P18 Self-reported prevalence of drug hypersensitivity reactions among students in Celal Bayar University, Turkey Ayse Aktas, Suheyla Rahman, Huseyin Elbi, Beyhan Cengiz Ozyurt P19 Severe drug hypersensitivity reactions in pediatric age Ozlem Cavkaytar, Betul Karaatmaca, Pinar Gur Cetinkaya, Saliha Esenboga, Umit M. Sahiner, Bulent E. Sekerel, Ozge Soyer Poster Walk 3: Desensitisation (P20–P28) P20 A protocol for desensitisation to valaciclovir Celia Zubrinich, Bianca Tong, Mittal Patel, Michelle Giles, Robyn O’Hehir, Robert Puy P21 A rare case of desensitization to modafinil Josefina Cernadas, Luís Amaral, Fabrícia Carolino P22 A sixteen-day desensitization protocol in delayed type hypersensitivity reactions to oral drugs Semra Demir, Asli Gelincik, Muge Olgac, Raif Caskun, Derya Unal, Bahauddin Colakoglu, Suna Buyukozturk P23 Desensitization to intravenous etoposide using a 12 and a 13-step protocol. Two cases report Olga Vega Matute, Amalia Bernad, Gabriel Gastaminza, Roselle Madamba, Carlos Lacasa, M. J. Goikoetxea, Carmen D’Amelio, Jose Rifón, Nicolas Martínez, Marta Ferrer P24 Drug desensitisation in oncology: the experience of an immunoallergology department for 5 years Carmelita Ribeiro, Emília Faria, Cristina Frutuoso, Anabela Barros, Rosário Lebre, Alice Pego, Ana Todo Bom P25 Filgrastim anaphylaxis: a successful desensitization protocol Luis Amaral, Josefina Cernadas P26 Galsulfase hypersensitivity and desensitization of a mucopolysaccharidosis VI patient Luis Felipe Ensina, Carolina Aranda, Ines Camelo Nunes, Ana Maria Martins, Dirceu Solé P27 Rapid drug desensitization with biologicals: one-center experience with four biologicals Sevim Bavbek, Resat Kendirlinan, Pamir Çerçi, Seda Tutluer, Sadan Soyyigit, Zeynep Çelebi Sözener, Ömür Aydin, Reyhan Gümüsburun P28 Successful desensitization to a high dose of methotrexate in a delayed type hypersensitivity reaction Josefina Cernadas, Leonor Carneiro-Leão, Fabrícia Carolino, Marta Almeida Poster Walk 4: SJS (P29–P38) P29 Assessment of impact of infection on drug-induced severe cutaneous adverse reactions and rhabdomyolysis using the Japanese adverse drug event report database Kimie Sai, Takuya Imatoh, Ryosuke Nakamura, Chisato Fukazawa, Yasushi Hinomura, Yoshiro Saito P30 Characterization of erythema multiforme and severe cutaneous adverse reactions hospitalizations Bernardo Sousa-Pinto, Cláudia Correia, Lídia Gomes, Sara Gil-Mata, Luís Araújo, Luís Delgado P31 Effects of infection on incidence/severity of SJS/TEN and myopathy in Japanese cases analyzed by voluntary case reports Ryosuke Nakamura, Kimie Sai, Takuya Imatoh, Yoshimi Okamoto-Uchida, Koji Kajinami, Kayoko Matsunaga, Michiko Aihara, Yoshiro Saito P32 Efficacy of tumor necrosis factor—a antagonists in Stevens–Johnson syndrome and toxic epidermal necrolysis: a randomized controlled trial and immunosuppressive effects evaluation Chuang-Wei Wang, Shih-Chi Su, Shuen-Iu Hung, Hsin-Chun Ho, Chih-Hsun Yang, Wen-Hung Chung P33 Evolution of drug causality in Stevens–Johnson syndrome and toxic epidermal necrolysis in Europe: analysis of 10 years RegiSCAR-Study Maren Paulmann, Ariane Dunant, Maja Mockenhaupt, Peggy Sekula, Martin Schumacher, Sylvia Kardaun, Luigi Naldi, Teresa Bellón, Daniel Creamer, Cynthia Haddad, Bruno Sassolas, Bénédicte Lebrun-Vignes, Laurence Valeyrie-Allanore, Jean-Claude Roujeau P34 Long-term sequelae in patients with Stevens–Johnson syndrome and toxic epidermal necrolysis: a 5-year analysis Maren Paulmann, Carmen Kremmler, Peggy Sekula, Laurence Valeyrie-Allanore, Luigi Naldi, Sylvia Kardaun, Maja Mockenhaupt P35 Major emotional complications and decreased health related quality of life among survivors of Stevens–Johnson syndrome and toxic epidermal necrolysis Roni P. Dodiuk-Gad, Cristina Olteanu, Anthony Feinstein, Rena Hashimoto, Raed Alhusayen, Sonia Whyte-Croasdaile, Yaron Finkelstein, Marjorie Burnett, Shachar Sade, Robert Cartotto, Marc Jeschke, Neil H. Shear P36 Retrospective analysis of Stevens–Johnson syndrome and toxic epidermal necrolysis in Japanese patients: treatment and outcome Naoko Takamura, Yumiko Yamane, Setsuko Matsukura, Kazuko Nakamura, Yuko Watanabe, Yukie Yamaguchi, Takeshi Kambara, Zenro Ikezawa, Michiko Aihara P37 Severe physical complications among survivors of Stevens–Johnson syndrome and toxic epidermal necrolysis Roni P. Dodiuk-Gad, Cristina Olteanu, Rena Hashimoto, Hall Chew, Raed Alhusayen, Sonia Whyte-Croasdaile, Yaron Finkelstein, Marjorie Burnett, Shachar Sade, Robert Cartotto, Marc Jeschke, Neil H. Shear P38 Stevens–Johnson syndrome/toxic epidermal necrolysis combined with haemophagocytic lymphohistiocytosis: a case report Brittany Knezevic, Una Nic Ionmhain, Allison Barraclough, Michaela Lucas, Matthew Anstey Poster Walk 5: Other organs/unexpected immune reactions (P39–P47) P39 A case report of patient with anti-tuberculosis drug-related severe liver failure Toru Usui, Xiaoli Meng, John Farrell, Paul Whitaker, John Watson, Neil French, Kevin Park, Dean Naisbitt P40 Acute interstitial nephritis induced by ibuprofen Ana Castro Neves, Susana Cadinha, Ana Moreira, J. P. Moreira Da Silva P41 Cetuximab induced acneiform rash—two case reports Daniela Ledic Drvar, Sandra Jerkovic Gulin, Suzana Ljubojevic Hadzavdic, Romana Ceovic P42 Enteropathy associated with losartan Ana Montoro De Francisco, Talía De Vicente Jiménez, Amelia García Luque, Natalia Rosado David, José Mª Mateos Galván P43 Granuloma annulare after therapy with canakinumab Razvigor Darlenski P44 Hypersensitivity eosinophilic myocarditis or acute coronary syndrome? Case report Dario Gulin, Jozica Sikic, Jasna Cerkez Habek, Sandra Jerkovic Gulin, Edvard Galic P45 Piperacillin-induced immune haemolytic anaemia: a severe and frequent complication of antibiotic treatment in patients with cystic fibrosis Philip Specht, Doris Staab, Beate Mayer, Jobst Roehmel P46 Progesterone triggered pemphigus foliaceus: case report Sandra Jerkovic Gulin, Caius Solovan, Anca Chiriac P47 Ramipril: triggered generalized pustular psoriasis Paola Djurinec, Kresimir Kostovic, Mirna Bradamante, Sandra Jerkovic Gulin, Romana Ceovic Poster Walk 6: NSAIDs (P48–P56) P48 Aspirin desensitization in cardiovascular disease—Portuguese experience Jose Pedro Almeida, Joana Caiado, Elisa Pedro, Pedro Canas Da Silva, Manuel Pereira Barbosa P49 Asthma and/or rhinitis to NSAIDs with good tolerance to ASA Gador Bogas, Natalia Blanca-López, Diana Pérez-Alzate, Inmaculada Doña, José Augusto Agúndez, Elena García-Martín, José Antonio Cornejo-García, Cristobalina Mayorga, María José Torres, Gabriela Canto, Miguel Blanca P50 Clinical characteristics of 196 patients with non-steroidal anti-inflammatory drug (NSAIDs) hypersensitivity Sengül Aksakal, Aytül Zerrin Sin, Zeynep Peker Koç, Fatma Düsünür Günsen, Ömür Ardeniz, Emine Nihal Mete Gökmen, Okan Gülbahar, Ali Kokuludag P51 Development of immediate hypersensitivity to several NSAIDs maintaining good tolerance to ASA Natalia Pérez-Sánchez, Natalia Blanca-López, Diana Pérez-Alzate, Gador Bogas, Inmaculada Doña, María Salas, María José Torres, Miguel Blanca, Gabriela Canto P52 Diagnosis of hypersensitivity reactions to paracetamol in a large series of cases Inmaculada Doña, Maria Salas, Francisca Gomez, Natalia Blanca-Lopez, Diana Perez-Alzate, Gador Bogas, Esther Barrionuevo, Maria Jose Torres, Inmaculada Andreu, Miguel Ángel Miranda, Gabriela Canto, Miguel Blanca P53 Hypersensitivity to paracetamol according to the new classification of hypersensitivity to NSAIDs Gabija Didžiokaite, Olesia Gaidej, Simona Kašinskaite, Violeta Kvedariene P54 Ibuprofen and other aryl propionic derivates can induce immediate selective hypersensitivity responses Diana Perez-Alzate, Natalia Blanca-López, Maria Isabel Garcimartin, Inmaculada Doña, Maria Luisa Somoza, Cristobalina Mayorga, Maria Jose Torres, Gador Bojas, Jose Antonio Cornejo-Garcia, Maria Gabriela Canto, Miguel Blanca P55 Subjects developing immediate responses to several NSAIDs can be selective with good tolerance to ASA Natalia Blanca-Lopez, Diana Pérez-Alzate, Francisco Javier Ruano Perez, Inmaculada Doña, Maria Luisa Somoza, Inmaculada Andreu, Miguel Angel Miranda, Cristobalina Mayorga, Maria Jose Torres, Jose Antonio Cornejo-Garcia, Miguel Blanca, Maria Gabriela Canto P56 Utility of low-dose oral aspirin challenges for diagnosis of aspirin exacerbated respiratory disease Elina Jerschow, Teresa Pelletier, Zhen Ren, Golda Hudes, Marek Sanak, Esperanza Morales, Victor Schuster, Simon D. Spivack, David Rosenstreich Poster Walk 7: NSAID 2 (P57–P65) P57 Alternate regulation of cyclooxygenase-2 (COX-2) MRNA expression may predispose patients to aspirin-induced exacerbations Renato Erzen, Mira Silar, Nissera Bajrovic, Matija Rijavec, Mihaela Zidarn, Peter Korosec P58 Anaphylaxis to diclofenac: what about the underlying mechanism? Leonor Carneiro-Leão, Fabrícia Carolino, Luís Amaral, Carmen Botelho, Eunice Dias-Castro, Josefina Cernadas P59 COX-2 inhibitors: are they always a safe alternative in hypersensitivity to nonsteroidal anti-inflammatory drugs? Luis Amaral, Fabricia Carolino, Eunice Castro, Josefina Cernadas P60 Management of patients with history of NSAIDs reactions prior to coronary angioplasty Mona Al-Ahmad, Tito Rodriguez P61 Oral drug challenge with non-steroidal anti-inflammatory drug under spirometric control: clinical series of 110 patients João Pedro Azevedo, Emília Faria, Beatriz Tavares, Frederico Regateiro, Ana Todo-Bom P62 Prevalence and incidence of analgesic hypersensitivity reactions in Colombia Pablo Andrés Miranda, Bautista De La Cruz Hoyos P63 Recent endoscopic sinus surgery lessens reactions during aspirin challenge in patients with aspirin exacerbated respiratory disease Teresa Pelletier, Waleed Abuzeid, Nadeem Akbar, Marc Gibber, Marvin Fried, Weiguo Han, Taha Keskin, Robert Tamayev, Golda Hudes, Simon D. Spivack, David Rosenstreich, Elina Jerschow P64 Safe use of imidazole salycilate in a case of multiple NSAIDs induced urticaria-angioedema Elisa Boni, Marina Russello, Marina Mauro P65 Selective hypersensitivity reactions to ibuprofen—seven years experience Marta Ferreira Neto Poster Walk 8: Epidemiological methods (P66–P72) P66 Allopurinol hypersensitivity: a 7-year review Lise Brosseron, Daniela Malheiro, Susana Cadinha, Patrícia Barreira, J. P. Moreira Da Silva P67 Antibiotic allergy labelling is associated with increased hospital readmission rates in Australia Brittany Knezevic, Dustin Sprigg, Michelle Trevenen, Jason Seet, Jason Trubiano, William Smith, Yogesh Jeelall, Sandra Vale, Richard Loh, Andrew Mclean-Tooke, Michaela Lucas P68 Experts’ opinions on severe cutaneous adverse drug reactions-report of a survey from the 9th international congress on cutaneous adverse drug reactions 2015 Roni P. Dodiuk-Gad, Cristina Olteanu, Wen-Hung Chung, Neil H. Shear P69 HLA-A*31-positive AGEP with carbamazepine use and other severe cutaneous adverse drug reactions (SCARs) detected by electronic medical records screening Sabine Müller, Ursula Amstutz, Lukas Jörg, Nikhil Yawalkar, Stephan Krähenbühl P70 Patients with suspected drug allergy: a specific psychological profile? Eunice Dias-Castro, Ana Leblanc, Laura Ribeiro, Josefina R. Cernadas P71 Use of an electronic device and a computerized mathematic algorithm to detect the allergic drug reactions through the analysis of heart rate variability Arantza Vega, Raquel Gutierrez Rivas, Ana Alonso, Juan Maria Beitia, Belén Mateo, Remedios Cárdenas, Juan Jesus Garcia-Dominguez P72 Variation in ERAP influences risk for HLA-B*57:01 positive abacavir hypersensitivity Rebecca Pavlos, Kaija Strautins, Ian James, Simon Mallal, Alec Redwood, Elizabeth Phillips Poster Walk 9: DRESS/AGEP (P73–P81) P73 A clinical case of DRESS syndrome in a child after administration of amoxicillin-clavulanic acid Rita Aguiar, Anabela Lopes, Ana Neves, Maria Do Céu Machado, M. A. Pereira-Barbosa P74 Acute generalized exanthematous pustulosis (AGEP) induced by mesalazine, reliable and oftenly used drug to treat inflammatory bowel disease Ceyda Tunakan Dalgiç, Emine Nihal Mete Gökmen, Fatma Düsünür Günsen, Gökten Bulut, Fatma Ömür Ardeniz, Okan Gülbahar, Ali Kokuludag, Aytül Zerrin Sin P75 Changes of blood plasmacytoid dendritic cells, myeloid dendritic cells, and basophils during the acute stage of drug reaction with eosinophilia and systemic symptoms (DRESS) and other drug eruptions Shao-Hsuan Hsu, Yung-Tsu Cho, Che-Wen Yang, Kai-Lung Chen, Chia-Yu Chu P76 Characterization of isoniazid/rifampicin-specific t-cell responses in patients with DRESS syndrome Young-Min Ye, Gyu-Young Hur, Hae-Sim Park, Seung-Hyun Kim P77 DRESS syndrome secondary to sulfasalazine with delayed TEN: a case presentation Syed Ali, Michaela Lucas, Peter N. Hollingsworth, Andrew P. C. Mclean-Tooke P78 Drug rash with eosinophilia and systemic symptoms (DRESS) features according to the culprit drug Zohra Chadly, Nadia Ben Fredj, Karim Aouam, Haifa Ben Romdhane, Naceur A. Boughattas, Amel Chaabane P79 Drug reaction with eosinophilia and systemic symptoms induced by allopurinol: not always easy to diagnose Marina Lluncor Salazar, Beatriz Pola, Ana Fiandor, Teresa Bellón, Elena Ramírez, Javier Domínguez Ortega, Santiago Quirce, Rosario Cabañas P80 Drug reaction with eosinophilia and systemic symptoms syndrome induced by two drugs simultaneously: a case report Krasimira Baynova, Marina Labella, Manuel Prados P81 The drug reaction with eosinophilia and systemic symptoms (DRESS) induced by the second-line antituberculosis drugs and Epstein–Barr virus infection Agne Ramonaite, Ieva Bajoriuniene, Brigita Sitkauskiene, Raimundas Sakalauskas Poster Walk 10: Miscellaneous drug hypersensitivity (P82–P91) P82 A case of cycloserine-induced lichenoid drug eruption confirmed with a lymphocatye transformation test Jae-Woo Kwon, Shinyoung Park P83 Allergic reaction to topical eye drops: 5 years’ retrospective study in a drug allergy unit Diana Silva, Leonor Carneiro Leão, Fabricia Carolino, Eunice Castro, Josefina Cernadas P84 Allergy to heparins Diana Perez-Alzate, Natalia Blanca-López, Maria Luisa Somoza Alvarez, Maria Garcimartin, Maria Vazquez De La Torre, Francisco Javier Ruano Pérez, Elisa Haroun, Gabriela Canto Diez P85 Allopurinol-induced adverse drug reactions Katinka Ónodi-Nagy, Ágnes Kinyó, Lajos Kemény, Zsuzsanna Bata-Csörgo P86 Analysis of a population with immediate hypersensitivity to corticosteroids: an 11 year review Joana Sofia Pita, Emília Faria, Rosa Anita Fernandes, Ana Moura, Nuno Sousa, Carmelita Ribeiro, Carlos Loureiro, Ana Todo Bom P87 Anaphylaxis against mivacurium in a 12-months old boy at first-time exposure Wolfgang Pfützner P88 Antihistamine-exacerbated chronic spontaneous urticaria: a paradox? Nadine Marrouche, Clive Grattan P89 Anti-osteoporotic agents-induced cutaneous adverse drug reactions in Asians Yu-En Chen, Chun-Bing Chen, Wen-Hung Chung, Yu-Ping Hsiao, Chia-Yu Chu P90 Diagnosis of allergic reactions to eye drops Maria Vazquez De La Torre, Natalia Blanca-Lopez, Diana Perez-Alzate, Maria Isabel Garcimartin, Francisco Javier Ruano, Maria Luisa Somoza, Elisa Haroun, Gabriela Canto P91 Diagnostic approach in suspected hypersensitivity reactions to corticosteroids Fabrícia Carolino, Eunice Dias De Castro, Josefina R. Cernadas
Collapse
|
40
|
Pieri L, Bonadonna P, Elena C, Papayannidis C, Grifoni FI, Rondoni M, Girlanda S, Mauro M, Magliacane D, Elli EM, Iorno ML, Almerigogna F, Scarfì F, Salerno R, Fanelli T, Gesullo F, Corbizi Fattori G, Bonifacio M, Perbellini O, Artuso A, Soverini S, De Benedittis C, Muratori S, Pravettoni V, Cova V, Cortellini G, Ciceri F, Cortelezzi A, Martinelli G, Triggiani M, Merante S, Vannucchi AM, Zanotti R. Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients. Am J Hematol 2016; 91:692-9. [PMID: 27060898 DOI: 10.1002/ajh.24382] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2016] [Accepted: 04/05/2016] [Indexed: 01/18/2023]
Abstract
Systemic mastocytosis is a rare heterogeneous myeloproliferative neoplasm characterized by abnormal proliferation and activation of mast cells. We describe a large multicentre series of 460 adult patients with systemic mastocytosis, with a diagnosis based on WHO 2008 criteria, in a "real-life" setting of ten Italian centers with dedicated multidisciplinary programs. We included indolent forms with (n = 255) and without (n = 165) skin lesions, smouldering (n = 20), aggressive (n = 28), associated with other hematological diseases mastocytosis (n = 21) and mast cell leukemia (n = 1). This series was uniquely characterized by a substantial proportion of patients with low burden of neoplastic mast cells; notably, 38% of cases were diagnosed using only minor diagnostic criteria according to WHO 2008 classification, underlying the feasibility of early diagnosis where all diagnostic approaches are made available. This has particular clinical relevance for prevention of anaphylaxis manifestations, that were typically associated with indolent forms. In multivariate analysis, the most important features associated with shortened overall survival were disease subtype and age at diagnosis >60 years. Disease progression was correlated with mastocytosis subtype and thrombocytopenia. As many as 32% of patients with aggressive mastocytosis suffered from early evolution into acute leukemia. Overall, this study provides novel information about diagnostic approaches and current presentation of patients with SM and underlines the importance of networks and specialized centers to facilitate early diagnosis and prevent disease-associated manifestations. Am. J. Hematol. 91:692-699, 2016. © 2016 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Lisa Pieri
- CRIMM Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero Universitaria Careggi, Department of Experimental and Clinical Medicine; DENOTHE Excellence Center, University of Florence; Florence Italy
| | - Patrizia Bonadonna
- Allergy Unit, Azienda Ospedaliera Universitaria Integrata of Verona; Verona Italy
| | - Chiara Elena
- Department of Molecular Medicine; University of Pavia
- Department of Hematology Oncology; Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | | | - Federica Irene Grifoni
- Fondazione IRCCS Ca‘Granda Ospedale Maggiore Policlinico; UOC Di Oncoematologia; Milano Italy
| | - Michela Rondoni
- Clinical Pathology Department; Azienda Unità Sanitaria Locale Della Romagna; Cesena Italy
| | | | | | - Diomira Magliacane
- Clinical Immunology and Allergoloy; University of Salerno; Salerno Italy
| | | | | | - Fabio Almerigogna
- Internal Medicine Section, Department of Experimental and Clinical Medicine; University of Florence; Florence Italy
| | - Federica Scarfì
- Dermatology Sect, Department of Translational Medicine and Surgery; University of Florence; Florence Italy
| | - Roberto Salerno
- Endocrinology Unit, Azienda Ospedaliera Universitaria Careggi; Florence Italy
| | - Tiziana Fanelli
- CRIMM Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero Universitaria Careggi, Department of Experimental and Clinical Medicine; DENOTHE Excellence Center, University of Florence; Florence Italy
- University of Siena, Doctorate in genetic, oncology and clinical medicine
| | - Francesca Gesullo
- CRIMM Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero Universitaria Careggi, Department of Experimental and Clinical Medicine; DENOTHE Excellence Center, University of Florence; Florence Italy
| | - Giuditta Corbizi Fattori
- CRIMM Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero Universitaria Careggi, Department of Experimental and Clinical Medicine; DENOTHE Excellence Center, University of Florence; Florence Italy
- University of Siena, Doctorate in genetic, oncology and clinical medicine
| | - Massimiliano Bonifacio
- Department of Medicine, Haematology Section; Azienda Ospedaliera Universitaria Integrata Di Verona; Verona Italy
| | - Omar Perbellini
- Department of Medicine, Haematology Section; Azienda Ospedaliera Universitaria Integrata Di Verona; Verona Italy
| | - Anna Artuso
- Department of Medicine, Haematology Section; Azienda Ospedaliera Universitaria Integrata Di Verona; Verona Italy
| | - Simona Soverini
- Institute of Hematology Seragnoli DIMES, University of Bologna; Bologna Italy
| | | | - Simona Muratori
- Department of Medical and Surgical Physiopathology; Physiopathology of Transplant, Milano, Italy, University of Milano
| | - Valerio Pravettoni
- Internal Medicine, Clinic Allergology and Immunology; Ospedale Maggiore Policlinico, IRCCS Ca' Granda Foundation; Milano Italy
| | - Vittoria Cova
- Clinical Pathology Department; Azienda Unità Sanitaria Locale Della Romagna; Cesena Italy
| | | | - Fabio Ciceri
- Department of Hematology; San Raffaele Hospital; Milano Italy
| | - Agostino Cortelezzi
- Hematology and Transplantation Unit, IRCCS Ca' Granda Foundation, Ospedale Maggiore Policlinico and University of Milan; Milano Italy
| | - Giovanni Martinelli
- Institute of Hematology Seragnoli DIMES, University of Bologna; Bologna Italy
| | - Massimo Triggiani
- Clinical Immunology and Allergoloy; University of Salerno; Salerno Italy
| | - Serena Merante
- Department of Molecular Medicine; University of Pavia
- Department of Hematology Oncology; Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | - Alessandro Maria Vannucchi
- CRIMM Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero Universitaria Careggi, Department of Experimental and Clinical Medicine; DENOTHE Excellence Center, University of Florence; Florence Italy
| | - Roberta Zanotti
- Department of Medicine, Haematology Section; Azienda Ospedaliera Universitaria Integrata Di Verona; Verona Italy
| |
Collapse
|
41
|
Mauro M, Boni E, Makri E, Incorvaia C. Pharmacodynamic and pharmacokinetic evaluation of house dust mite sublingually administered immunotherapy tablet in the treatment of asthma. Expert Opin Drug Metab Toxicol 2015; 11:1937-43. [PMID: 26565665 DOI: 10.1517/17425255.2015.1113255] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
INTRODUCTION Sublingual immunotherapy (SLIT) for house dust mite (HDM) allergy has an evidence of efficacy demonstrated by meta-analyses, but marked differences are reported between the various SLIT products. The standardized quality (SQ) HDM sublingual tablet containing Dermatophagoides pteronyssinus and Dermatophagoides farinae in a 1:1 ratio (MK-8237) is a qualitative advance for SLIT products. AREAS COVERED The rationale for developing the HDM tablets is discussed against the other available SLIT products, analyzing the clinical data on efficacy and safety obtained by controlled trials. EXPERT OPINION Following preliminary Phase I and II studies, a double-blind, placebo-controlled trial on 604 patients with mite-induced asthma, aged more than 14 years and treated by inhaled budesonide, was performed using one of three active doses (1, 3 or 6 SQ) or placebo. The results showed a significant mean difference between 6 SQ-HDM and placebo in the reduction in daily budesonide dose of 81 µg (p = 0.004), with relative mean and median reductions of 42 and 50% for 6 SQ-HDM and 15 and 25% for placebo, respectively. Safety was very good, with no report of anaphylactic reaction. These findings suggest a role to the HDM SLIT tablets in the treatment of patients with mite-induced asthma.
Collapse
Affiliation(s)
- Marina Mauro
- a Allergy Unit , Sant'Anna Hospital , Como , Italy
| | - Elisa Boni
- a Allergy Unit , Sant'Anna Hospital , Como , Italy
| | - Elena Makri
- b Allergy/Pulmonary Rehabilitation , ICP Hospital , Milan 20100 , Italy
| | | |
Collapse
|
42
|
Abstract
Sublingual immunotherapy (SLIT) was introduced in the 1980s as a safer option to subcutaneous immunotherapy and in the latest decade achieved significant advances. Its efficacy in allergic rhinitis is supported by a number of meta-analyses. The development of SLIT preparations in tablets to fulfill the requirements of regulatory agencies for quality of allergen extracts made available optimal products for grass-pollen-induced allergic rhinitis. Preparations of other allergens based on the same production methods are currently in progress. A notable outcome of SLIT, that is shared with subcutaneous immunotherapy, is the evident cost–effectiveness, showing significant cost savings as early as 3 months from starting the treatment, that become as high as 80% compared with drug treatment in the ensuing years.
Collapse
Affiliation(s)
- Cristoforo Incorvaia
- Allergy/Pulmonary Rehabilitation, ICP Hospital, via Bignami 1, 20100 Milan, Italy
| | | | - Erminia Ridolo
- Department of Clinical & Experimental Medicine, University of Parma, Parma, Italy
| |
Collapse
|
43
|
Guadagno L, Raimondo M, Vertuccio L, Mauro M, Guerra G, Lafdi K, De Vivo B, Lamberti P, Spinelli G, Tucci V. Optimization of graphene-based materials outperforming host epoxy matrices. RSC Adv 2015. [DOI: 10.1039/c5ra04558d] [Citation(s) in RCA: 64] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Graphitic layers are designed as a self-assembly structure using edge-carboxylated layers approach. The functionalization facilitate the interfacial interaction between polymer and carbon layers enhancing electrical and mechanical performance.
Collapse
Affiliation(s)
- L. Guadagno
- Department of Industrial Engineering
- University of Salerno
- Fisciano (SA) 84084
- Italy
| | - M. Raimondo
- Department of Industrial Engineering
- University of Salerno
- Fisciano (SA) 84084
- Italy
| | - L. Vertuccio
- Department of Industrial Engineering
- University of Salerno
- Fisciano (SA) 84084
- Italy
| | - M. Mauro
- Department of Chemistry and Biology
- University of Salerno
- Fisciano (SA)
- Italy
| | - G. Guerra
- Department of Chemistry and Biology
- University of Salerno
- Fisciano (SA)
- Italy
| | - K. Lafdi
- University of Dayton
- Dayton Ohio
- USA
| | - B. De Vivo
- Department of Information Engineering
- Electrical Engineering and Mathematics Applied University of Salerno
- Fisciano (SA)
- Italy
| | - P. Lamberti
- Department of Information Engineering
- Electrical Engineering and Mathematics Applied University of Salerno
- Fisciano (SA)
- Italy
| | - G. Spinelli
- Department of Information Engineering
- Electrical Engineering and Mathematics Applied University of Salerno
- Fisciano (SA)
- Italy
| | - V. Tucci
- Department of Information Engineering
- Electrical Engineering and Mathematics Applied University of Salerno
- Fisciano (SA)
- Italy
| |
Collapse
|
44
|
Prock J, Strabler C, Viertl W, Kopacka H, Obendorf D, Müller T, Tordin E, Salzl S, Knör G, Mauro M, De Cola L, Brüggeller P. Unusual stability of dyads during photochemical hydrogen production. Dalton Trans 2015; 44:20936-48. [DOI: 10.1039/c5dt03414k] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Heterodimetallic dyads containing Os and Pd are connected by a bis(bidentate) phosphine and show an excellent stability for the water splitting application.
Collapse
|
45
|
Incorvaia C, Mauro M, Ridolo E, Makrì E, Montagni M, Ciprandi G. A Pitfall to Avoid When Using an Allergen Microarray: The Incidental Detection of IgE to Unexpected Allergens. J Allergy Clin Immunol Pract 2014; 3:879-82. [PMID: 25609332 DOI: 10.1016/j.jaip.2014.09.020] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/24/2014] [Revised: 09/14/2014] [Accepted: 09/18/2014] [Indexed: 12/23/2022]
Abstract
The introduction of new laboratory techniques to detect specific IgE antibodies against single allergen molecules rather than whole extracts represents a significant advance in allergy diagnostics. The advantages of such component-resolved diagnosis can be summarized as follows: (1) the ability to identify the truly responsible allergens in polysensitized patients, whether they be genuine (causing specific sensitization to their corresponding allergen source) or primary (the original sensitizing molecule); (2) distinguishing these allergens from simply cross-reactive components; (3) improving the appropriateness of the prescribed specific immunotherapy; and (4) identifying a risk profile for food allergens. Component-resolved diagnosis is performed using either a singleplex (1 assay per sample) platform or a multiplex (multiple assays per sample) platform. Using an immuno solid-phase allergen chip microarray that falls into the latter category--it currently tests sensitivity to 112 allergens--may lead to a pitfall: detecting IgE to unexpected allergens, such as Hymenoptera venom. In fact, testing insect venom sensitivity in individuals with no history of reactions to stings is contrary to current guidelines and presents the physician with the dilemma of how to manage this information; moreover, this may become a legal issue. Based on what is currently known about venom allergy, it remains likely that a positive sensitization test result will have no clinical significance, but the possibility of reacting to a future sting cannot be completely ruled out. Because this problem has not been previously encountered using the more common allergy tests, no indications are currently available on how to effectively manage these cases.
Collapse
Affiliation(s)
| | - Marina Mauro
- Allergy Service, Sant'Anna Hospital, Como, Italy
| | - Erminia Ridolo
- Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy
| | - Eleni Makrì
- Allergy/Pulmonary Rehabilitation, ICP Hospital, Milan, Italy
| | - Marcello Montagni
- Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy
| | - Giorgio Ciprandi
- Medicine Department, Istituto di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliera Universitaria San Martino, Genoa, Italy.
| |
Collapse
|
46
|
Abstract
A large number of trials show that the anti-immunoglobulin (Ig) E antibody omalizumab is very effective in patients with severe allergic asthma. This is acknowledged in consensus documents. The drug also has a good safety profile and a pharmacoeconomic advantage due to a reduction in the number of hospitalizations for asthma attacks. In recent years, some studies have shown that omalizumab is effective also in nonallergic asthma. Effects on the complex signaling mechanisms leading to activation of effector cells and to mediator release may account for this outcome. Indeed, omalizumab has been reported to be effective in a number of IgE-mediated and non-IgE-mediated disorders. Concerning the former, clinical efficacy has been observed in rhinitis, allergic bronchopulmonary aspergillosis, latex allergy, atopic dermatitis, allergic urticaria, and anaphylaxis. In addition, omalizumab has been demonstrated to be able to prevent systemic reactions to allergen immunotherapy, thus enabling completion of treatment in patients who otherwise would have to stop it. Concerning non-IgE-mediated disorders, omalizumab has been reported to be effective in nasal polyposis, autoimmune urticaria, chronic idiopathic urticaria, physical urticaria, idiopathic angioedema, and mastocytosis. Current indications for treatment with omalizumab are confined to severe allergic asthma. Consequently, any other prescription can only be off-label. However, it is reasonable to expect that the use of omalizumab will be approved for particularly important indications, such as anaphylaxis, in the near future.
Collapse
Affiliation(s)
- Cristoforo Incorvaia
- Allergy/Pulmonary Rehabilitation, Istituti Clinici di Perfezionamento Hospital, Milan, Italy
| | | | | | | | | | - Erminia Ridolo
- Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy
| |
Collapse
|
47
|
Compalati E, Ortolani C, Pastorello E, Moscato G, Berra D, Tosi A, Mauro M. Poster 1000: Efficacy and safety of specific sublingual immunotherapy with carbamylated allergoid tablets of ragweed pollen: a dose-ranging study. World Allergy Organ J 2014. [PMCID: PMC4082075 DOI: 10.1186/1939-4551-7-s1-p1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
48
|
Incorvaia C, Barbera S, Makrì E, Mauro M. [Allergic rhinitis: pathology of general interest]. Recenti Prog Med 2013; 104:116-9. [PMID: 23548956 DOI: 10.1701/1255.13860] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Allergic rhinitis may appear of little value but at present its high and still increasing prevalence, its socio-economic burden, the frequent association with asthma and the significant impairment of quality of life in affected patients make it a disease of general importance. The ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines allow to properly recognize the mild forms and the moderate/severe forms, and, based on the duration of symptoms, the intermittent and persistent forms. Etiologic diagnosis can be suspected by history data but the certainty can be achieved only by allergy testing. The treatment is mainly based on oral or nasal topical antihistamines and topical corticosteroids, that ensure in most cases a satisfactory control of symptoms. However, there are patients who have an insufficient response to drugs, event at high doses. Recent studies showed that patients not controlled by drug treatment achieve a significant benefit from allergen specific immunotherapy, currently available by the subcutaneous and sublingual route. This should be considered as a criterion to choose patients for specific immunotherapy, who must be referred to the allergy specialist.
Collapse
|
49
|
Mauro M, Incorvaia C, Formigoni C, Elia R, Russello M, Pellegrino D. The anti-IgE antibody omalizumab as a probe to investigate the role of IgE in pathology. Panminerva Med 2012; 54:305-312. [PMID: 23123583] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
The immunoglobulin E (IgE) are a key factor in the pathophysiology of allergic diseases and the important therapeutic role of an anti-IgE antibody was long envisioned. It took time and efforts to solve the safety problems related to the anaphylactogen capacity of anti-IgE, finally crowned by the introduction of the humanized, monoclonal anti-IgE antibody omalizumab. Currently, omalizumab is indicated, based on clear evidence of efficacy, only in severe allergic asthma not controlled by conventional treatment. However, a continuously increasing amount of literature shows that omalizumab is efficacious in a number of disorders concerning the upper and lower airway and the skin, and, most importantly, in anaphylaxis. The latter application was demonstrated successful in placebo-controlled trials and warrants for a new, life-saving, indication for omalizumab. Also, the systemic reactions precluding the performance of allergen immunotherapy, especially concerning Hymenoptera venom, were prevented by omalizumab treatment. The most surprising success of omalizumab regards clinical conditions thus far considered unrelated to IgE antibodies. This is true for intrinsic asthma and for idiopathic urticaria (demonstrated by a placebo-controlled trial), and angioedema, suggesting in these condition a pathophysiologic role of IgE. These observations support a off-label use of omalizumab in patients suffering from IgE-related pathologies other than asthma who are at risk of fatal events or are uncontrolled by the optimal standard treatment.
Collapse
Affiliation(s)
- M Mauro
- Allergy Unit, Sant'Anna Hospital, Como, Italy
| | | | | | | | | | | |
Collapse
|
50
|
Incorvaia C, Mauro M, Monsalve RI, Vega A, Marqués L, Miranda A, Fernández J, Soriano V, Cruz S, Domínguez-Noche C, Sánchez-Morillas L, Armisen-Gil M, Guspí R, Barber D. Can component-resolved diagnosis overturn the current knowledge on vespid allergy? Allergy 2012; 67:966; author reply 966-7. [PMID: 22676064 DOI: 10.1111/j.1398-9995.2012.02839.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- C. Incorvaia
- Allergy/Pulmonary Rehabilitation Unit; ICP Hospital; Milan; Italy
| | - M. Mauro
- Allergy Unit; Sant'Anna Hospital; Como; Italy
| | | | - A. Vega
- Hospital Universitario de Guadalajara; Guadalajara; Spain
| | - L. Marqués
- Hospital Santa Maria - Universitari Arnau de Vilanova; Lleida; Spain
| | | | - J. Fernández
- Hospital General Universitario de Alicante; Alicante; Spain
| | - V. Soriano
- Hospital General Universitario de Alicante; Alicante; Spain
| | - S. Cruz
- Hospital Torrecardenas; Almería; Spain
| | | | | | - M. Armisen-Gil
- Hospital Provincial de Santiago de Compostela; Santiago de Compostela; Spain
| | - R. Guspí
- Hospital de Tortosa; Verge de la Cinta; Institut de Investigació Sanitaria Pere i Virgili (IISPV); Tortosa; Spain
| | | |
Collapse
|